EPIRUS Biopharmaceuticals (EPRSQ) 10-Q 10 Nov 14 2014 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
	Sep. 30, 2014	Nov. 07, 2014
Document and Entity Information	'	'
Entity Registrant Name	'EPIRUS Biopharmaceuticals, Inc.	'
Entity Central Index Key	'0001135906	'
Document Type	'10-Q	'
Document Period End Date	30-Sep-14	'
Amendment Flag	'false	'
Current Fiscal Year End Date	'--12-31	'
Entity Current Reporting Status	'Yes	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Common Stock, Shares Outstanding	'	12,934,102
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q3	'

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$23,681	$1,798
Prepaid expenses and other current assets	1,958	888
Total current assets	25,639	2,686
Property and equipment, net	665	90
In-process research and development	5,500	2,437
Intangible assets, net	3,661	'
Goodwill	16,363	1,499
Restricted cash	1,825	25
Other assets	187	57
Total assets	53,840	6,794
Current liabilities:	'	'
Accounts payable	1,760	1,067
Accrued expenses	4,626	2,492
Other current liabilities	295	'
Convertible notes	'	12,500
Deferred tax benefit	185	185
Total current liabilities	6,866	16,244
Warrant liability	'	5,843
Deferred revenue, net of current portion	1,000	'
Deferred tax liability	2,166	'
Deferred tax benefit, net of current portion	600	738
Other non-current liabilities	813	'
Stockholders' equity (deficit):	'	'
Preferred stock $0.001 par value; Authorized - 5,000,000 shares; Issued and Outstanding--0 shares	'	'
Common stock, $0.001 par value; Authorized--300,000,000 shares; Issued--12,934,102 and 237,026 shares at September 30, 2014 and December 31, 2013, respectively; Outstanding--12,920,843 and 237,026 shares at September 30, 2014 and December 31, 2013, respectively	13	'
Additional paid-in capital	118,554	5,348
Accumulated deficit	-76,172	-44,727
Total stockholders' equity (deficit)	42,395	-39,379
Total liabilities, convertible preferred stock and stockholders' equity (deficit)	53,840	6,794
Series A Convertible Preferred Stock [Member]	'	'
Current liabilities:	'	'
Series A convertible preferred stock, $0.0001 par value; Authorized-- 0 and 55,653,728 shares at September 30, 2014 and December 31, 2013; Issued and Outstanding-- 0 and 27,248,746 shares at September 30, 2014 and December 31, 2013, respectively; aggregate liquidation preference of $0 and $27,249 at September 30, 2014 and December 31, 2013, respectively	'	$23,348

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, except Share data, unless otherwise specified
Preferred stock (par value)	$0.00	$0.00
Preferred stock - shares issued	0	0
Preferred stock - shares outstanding	0	0
Common stock (par value)	$0.00	$0.00
Common stock - shares authorized	300,000,000	300,000,000
Common stock - shares issued	12,934,102	237,026
Common stock - shares outstanding	12,920,843	237,026
Series A Convertible Preferred Stock [Member]	'	'
Convertible preferred stock (par value)	$0.00	$0.00
Convertible preferred stock - shares authorized	0	55,653,728
Convertible preferred stock - shares issued	0	27,248,746
Convertible preferred stock - shares outstanding	0	27,248,746
Convertible preferred stock aggregate liquidation preference	$0	$27,249

Condensed_Consoldiated_Stateme

Condensed Consoldiated Statements of Operations and Comprehensive Loss (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Operating expenses:	'	'	'	'
Research and development	$5,397	$1,928	$11,488	$7,227
General and administrative	8,532	1,098	17,612	3,410
Total operating expenses	13,929	3,026	29,100	10,637
Loss from operations	-13,929	-3,026	-29,100	-10,637
Other income (expense):	'	'	'	'
Interest income (expense)	1	-589	-2,390	-1,596
Change in fair value of warrant liability	-23	-679	-222	-805
Other income, net	-5	'	285	'
Total other income (expense), net	-27	-1,268	-2,327	-2,401
Loss before income taxes	-13,956	-4,294	-31,427	-13,038
Benefit (loss) from income taxes	21	16	-18	16
Net loss	-13,935	-4,278	-31,445	-13,022
Net loss per share - basic and diluted	($1.28)	($18.05)	($8.15)	($55.38)
Weighted average number of common shares used in net loss per share calculation--basic and diluted	10,846,655	237,026	3,857,027	235,123
Comprehensive loss	($13,935)	($4,278)	($31,445)	($13,022)

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Changes in Stockholders' Equity (USD $)	Hercules Notes Member	Hercules Notes Member	Series A Convertible Preferred Stock [Member]	Series B Convertible Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
In Thousands, except Share data, unless otherwise specified	Additional Paid-in Capital [Member]
Balance at beginning of the period at Dec. 31, 2013	'	'	'	'	'	$5,348	($44,727)	($39,379)
Balance at beginning of the period at Dec. 31, 2013	'	'	23,348	'	'	'	'	'
Balance at beginning of the period (in shares) at Dec. 31, 2013	'	'	27,248,746	'	'	'	'	'
Balance at beginning of the period (in shares) at Dec. 31, 2013	'	'	'	'	237,026	'	'	237,026
Increase (Decrease) in Stockholders' Equity	'	'	'	'	'	'	'	'
Exercise of preferred stock warrant	'	'	6,436	993	'	'	'	'
Exercise of preferred stock warrant (in shares)	'	'	5,101,816	787,402	'	'	'	'
Issuance of preferred stock	'	'	13,184	30,478	'	'	'	'
Issuance of preferred stock ( in shares)	'	'	13,184,383	24,409,444	'	'	'	'
Issuance of convertible notes	'	'	'	'	'	2,071	'	2,071
Extinguishment of convertible notes	'	'	'	5,013	'	-1,150	'	-1,150
Extinguishment of convertible notes (in shares)	'	'	'	3,947,363	'	'	'	'
Exchange of preferred stock for common stock	'	'	-42,968	-36,484	10	79,442	'	79,452
Exchange of preferred stock for common stock ( in shares)	'	'	-45,534,945	-29,144,209	9,901,700	'	'	'
Issuance of common stock in connection with the Merger	'	'	'	'	3	31,321	'	31,324
Issuance of common stock in connection with the Merger ( in shares)	'	'	'	'	2,610,871	'	'	'
Exchange of warrants in connection with the Merger	248	248	'	'	'	167	'	167
Exercise of stock options	'	'	'	'	'	90	'	90
Exercise of stock options (in shares)	'	'	'	'	98,405	'	'	'
Issuance of common stock upon vesting of restricted stock units	'	'	'	'	'	-297	'	-297
Issuance of common stock upon vesting of restricted stock units ( in shares)	'	'	'	'	27,540	'	'	'
Stock-based compensation expense and vesting of restricted stock	'	'	'	'	'	1,314	'	1,314
Stock-based compensation expense and vesting of restricted stock ( in shares)	'	'	'	'	45,301	'	'	'
Comprehensive loss	'	'	'	'	'	'	-31,445	-31,445
Balance at end of the period at Sep. 30, 2014	'	'	'	'	$13	$118,554	($76,172)	$42,395
Balance at end of the period (in shares) at Sep. 30, 2014	'	'	0	'	'	'	'	'
Balance at end of the period (in shares) at Sep. 30, 2014	'	'	'	'	12,920,843	'	'	12,920,843

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Cash Flows (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013
Cash flows from operating activities:	'	'
Net loss	($31,445)	($13,022)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'
Depreciation and amortization	66	22
Non-cash interest expense	2,354	1,253
Stock-based compensation and vesting of restricted stock	1,314	93
Extinguishment of convertible notes	-22	'
Deferred taxes	-138	-36
Change in fair value of warrants	222	805
Other non-cash activity	66	32
Changes in operating assets and liabilities:	'	'
Prepaid expenses and other current assets	-599	-191
Restricted cash	50	'
Other non-current assets	-130	-82
Accounts payable	-897	1,171
Accrued expenses	880	964
Other non-current liabilities	-84	'
Deferred revenue	1,000	'
Net cash used in operating activities	-27,363	-8,991
Cash flows from investing activities	'	'
Cash acquired in acquisition	13,756	'
Purchases of property and equipment	-115	-82
Net cash provided by (used) in investing activities	13,641	-82
Cash flows from financing activities	'	'
Proceeds from the issuance of preferred stock and warrants	30,478	'
Proceeds from the issuance of convertible notes	5,000	7,500
Proceeds from the exercise of preferred stock warrants	334	5
Proceeds from the exercise of common stock warrants	'	3
Repurchases of common stock	-297	'
Proceeds from the exercise of common stock options	90	21
Net cash provided by financing activities	35,605	7,529
Net increase (decrease) in cash and cash equivalents	21,883	-1,544
Cash and cash equivalents - Beginning of period	1,798	2,234
Cash and cash equivalents - End of period	23,681	690
Supplemental schedule of non-cash investing and financing activities:	'	'
Conversion of convertible debt and accrued interest into preferred stock and warrants	13,184	'
Extinguishment of convertible debt and accrued interest into preferred stock	5,013	'
Exercise of warrants into preferred stock	7,095	499
Conversion of preferred stock into common stock	79,452	'
Conversion of preferred stock warrants to equity	168	'
Issuance of warrants in connection with Hercules debt	248	'
Leasehold improvements incurred by landlord	477	'
Fair value of assets acquired in Merger	36,223	'
Fair value of liabilities assumed in Merger	-4,899	'
Fair value of net assets acquired in Merger	$31,324	'

Organization

Organization	9 Months Ended
	Sep. 30, 2014
Organization	'
Organization	'
	1.Organization
	On July 15, 2014 EPIRUS Biopharmaceuticals, Inc., a Delaware corporation and private company (“Private Epirus”), completed its merger with EB Sub, Inc., a wholly-owned subsidiary of Zalicus Inc., a Delaware corporation (“Zalicus”), pursuant to the terms of that certain Agreement and Plan of Merger and Reorganization (as amended, the “Merger Agreement”), dated as of April 15, 2014, by and among Private Epirus, Zalicus and EB Sub, Inc., formerly known as BRunning, Inc. (the “Merger”). As part of the Merger, Zalicus was renamed EPIRUS Biopharmaceuticals, Inc. (“Public Epirus”) and Private Epirus was renamed EB Sub, Inc. (“EB Sub”).  The boards of directors of Private Epirus and Zalicus approved the Merger on April 15, 2014, and the stockholders of Private Epirus and Zalicus approved the Merger and related matters on July 15, 2014. Following completion of the Merger, Private Epirus, now known as EB Sub, Inc., is the surviving corporation of the Merger and a wholly-owned subsidiary of Public Epirus.
	The term “Company” as used in these notes to condensed consolidated financial statements refers to Private Epirus prior to the completion of the Merger and Public Epirus subsequent to the completion of the Merger.
	Prior to the Merger, Zalicus was a biopharmaceutical company developing drug candidates with a focus on the treatment of pain. Following the Merger, Public Epirus became a commercial-stage biotechnology company focused on improving patient access to important biopharmaceuticals by developing, manufacturing, and commercializing biosimilar therapeutics, or biosimilars, in targeted geographies worldwide. The Company has a principal place of business in Boston, Massachusetts. To date, the Company has devoted substantially all of its resources to the development of its drug discovery technologies and the research and development of its drug candidates, including conducting preclinical and clinical trials. The Company focuses on the development of biosimilar monoclonal antibodies (MAbs) for markets outside of North America and Japan. The Company’s lead product candidate is BOW015, a biosimilar version of Remicade (infliximab). Remicade, marketed by Johnson & Johnson, Merck Schering and Mitsubishi Tanabe for the treatment of various inflammatory diseases, achieved approximately $8.4 billion in global sales in 2013. In March 2014, the Company’s manufacturing partner, Reliance Life Sciences Pvt Ltd, or RLS, obtained marketing approval and in July 2014, received manufacturing approval in India for BOW015 as a treatment for rheumatoid arthritis. In July 2014, the Company received product label approval by the Drug Controller General of India. The Company has reported positive bioequivalence and efficacy data in the clinical development program for BOW015, including a Phase 1 clinical trial in the United Kingdom and in an interim analysis for a Phase 3 clinical trial in India, in each case showing equivalence with Remicade. The Company’s pipeline of biosimilar product candidates also includes BOW050, a biosimilar version of Humira (adalimumab), which is marketed by AbbVie and used to treat inflammatory diseases, and BOW030, a biosimilar version of Avastin (bevacizumab), which is marketed by Genentech/Roche and used to treat a variety of cancers and two additional undisclosed preclinical assets. Both BOW050 and BOW030 are in preclinical development. Collectively, Remicade, Humira and Avastin generated $26.2 billion in global sales in 2013 according to EvaluatePharma. In August 2013, the Company transferred all of its intellectual property to its subsidiary, Epirus Switzerland GmbH, a Swiss corporation.

Basis_of_Presentation

Basis of Presentation	9 Months Ended
	Sep. 30, 2014
Basis of Presentation	'
Basis of Presentation	'
	2.Basis of Presentation
	The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial reporting and as required by Regulation S-X, Rule 10-01. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments (including those which are normal and recurring) considered necessary for a fair presentation of the interim financial information have been included. When preparing financial statements in conformity with GAAP, the Company must make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses and related disclosures at the date of the financial statements. Actual results could differ from those estimates. Additionally, operating results for the three and nine months ended September 30, 2014 are not necessarily indicative of the results that may be expected for any other interim period or for the fiscal year ending December 31, 2014. For further information, refer to the consolidated financial statements and footnotes included in the Company’s annual consolidated financial statements for the year ended December 31, 2013, which are included in Public Epirus’ Current Report on Form 8-K filed with the Securities and Exchange Commission (“SEC”) on July 15, 2014.
	Merger and Exchange Ratio
	The Merger has been accounted for as a “reverse merger” under the acquisition method of accounting for business combinations with Private Epirus treated as the accounting acquirer of Zalicus. The historical financial statements of Private Epirus have become the historical financial statements of Public Epirus, or the combined company, and are included in this filing labeled EPIRUS Biopharmaceuticals, Inc. As a result of the Merger, historical common stock, stock options and additional paid-in capital, including share and per share amounts, have been retroactively adjusted to reflect the equity structure of Public Epirus, including the effect of the Merger exchange ratio and the Public Epirus common stock par value of $0.001 per share. See Note 5, “Merger,” for additional discussion of the Merger and the exchange ratio.
	Reverse Stock Split
	On July 16, 2014, Public Epirus effected a 1-for-10 reverse stock split of its outstanding common stock, par value $0.001 per share (“Public Epirus Common Stock”) (the “Reverse Stock Split”). The accompanying condensed consolidated financial statements and notes to the condensed consolidated financial statements, including the Merger exchange ratio (Note 5) applied to historical Private Epirus common stock and stock options, give retroactive effect to the Reverse Stock Split for all periods presented. The shares of Public Epirus Common Stock retained a par value of $0.001 per share.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2014
Summary of Significant Accounting Policies (Policies)	'
Summary of Significant Accounting Policies	'
	3.Summary of Significant Accounting Policies
	In the nine months ended September 30, 2014, there were no changes to the Company’s significant accounting policies identified in the Company’s most recent annual consolidated financial statements for the fiscal year ended December 31, 2013, which are included in Public Epirus’ Current Report on Form 8-K filed with the SEC on July 15, 2014, except as described below:
	Revenue Recognition
	Multiple-Element Arrangements
	Under the authoritative guidance for revenue recognition related to multiple-element revenue arrangements, each deliverable within a multiple-element revenue arrangement is accounted for as a separate unit of accounting if both of the following criteria are met: (1) the delivered item or items have value to the customer on a standalone basis and (2) for an arrangement that includes a general right of return relative to the delivered item(s), delivery or performance of the undelivered item(s) is considered probable and substantially in the Company’s control. The Company considers a deliverable to have standalone value if the Company sells this item separately or if the item is sold by another vendor or could be resold by the customer. Deliverables not meeting the criteria for being a separate unit of accounting are accounted for on a combined basis.
	In the event the Company enters into a contract in which the deliverables are required to be separated, the Company will allocate arrangement consideration to each deliverable in an arrangement based on its relative selling price. The Company determines selling price using vendor-specific objective evidence (“VSOE”), if it exists; otherwise, the Company uses third-party evidence (“TPE”). If neither VSOE nor TPE of selling price exists for a deliverable, the Company uses estimated selling price (“ESP”) to allocate the arrangement consideration. The Company applies appropriate revenue recognition guidance to each unit of accounting.
	Milestones
	Contingent consideration from research and development activities that is earned upon the achievement of a substantive milestone is recognized in its entirety in the period in which the milestone is achieved. At the inception of each arrangement that includes milestone payments, the Company evaluates whether each milestone is substantive. This evaluation includes an assessment of whether: (a) the consideration is commensurate with either (1) the entity’s performance to achieve the milestone, or (2) the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting from the entity’s performance to achieve the milestone, (b) the consideration relates solely to past performance and (c) the consideration is reasonable relative to all of the deliverables and payment terms within the arrangement. The Company evaluates factors such as the scientific, clinical, regulatory, commercial and other risks that must be overcome to achieve the respective milestone, the level of effort and investment required and whether the milestone consideration is reasonable relative to all deliverables and payment terms in the arrangement in making this assessment.
	In-process Research & Development
	In-process research & development (“IPR&D”) represents the fair value assigned to research and development assets that were not fully developed at the date of acquisition. IPR&D acquired in a business combination or recognized from the application of push-down accounting is capitalized on the Company’s consolidated balance sheet at its acquisition-date fair value. Until the project is completed, the assets are accounted for as indefinite-lived intangible assets and subject to impairment testing. Upon completion of a project, the carrying value of the related IPR&D is reclassified to intangible assets and is amortized over the estimated useful life of the asset.
	When performing the impairment assessment, the Company first assesses qualitative factors to determine whether it is necessary to recalculate the fair value of its acquired IPR&D. If the Company believes, as a result of the qualitative assessment, that it is more likely than not that the fair value of acquired IPR&D is less than its carrying amount, it calculates the asset’s fair value. If the carrying value of the Company’s acquired IPR&D exceeds its fair value, then the intangible asset is written down to its fair value. For the nine months ended September 30, 2014, the Company determined that there was no impairment of its IPR&D.
	Intangible Assets
	The Company amortizes its intangible assets using the straight-line method over its estimated economic life, which is approximately 16.5 years. The Company evaluates the potential impairment of its other intangible assets if events or changes in circumstances indicate that the carrying amount of the assets may not be fully recoverable or that the useful life of the assets is no longer appropriate. The impairment test is based on a comparison of the undiscounted cash flows expected to be generated from the use of the asset group and its eventual disposition to the carrying value of the asset group. If impairment is indicated, the assets are written down by the amount by which the carrying value of the assets exceeds the related fair value of the assets. Any write-downs are treated as permanent reductions in the carrying value of the assets.
	Recent Accounting Pronouncements
	Revenue Recognition
	In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers, which amends the guidance for accounting for revenue from contracts with customers. This ASU supersedes the revenue recognition requirements in Accounting Standards Codification Topic 605, Revenue Recognition, and creates a new Topic 606, Revenue from Contracts with Customers. This guidance is effective for fiscal years beginning after December 15, 2016, with early adoption not permitted. Two adoption methods are permitted: retrospectively to all prior reporting periods presented, with certain practical expedients permitted; or retrospectively with the cumulative effect of initially adopting the ASU recognized at the date of initial application. The Company has not yet determined which adoption method it will utilize or the effect that the adoption of this guidance will have on its consolidated financial statements.
	Discontinued Operations and Disposals
	In April 2014, the FASB issued ASU No. 2014-8, Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity (“ASU 2014-8”). ASU 2014-8 changes the criteria for determining which disposals can be presented as discontinued operations and modifies related disclosure requirements. Under the new guidance, a discontinued operation is defined as a disposal of a component or group of components that is disposed of or is classified as held for sale and represents a strategic shift that has a major effect on an entity’s operations and financial results. This accounting guidance applies prospectively to new disposals and new classifications of disposal groups as held for sale. The guidance is effective for fiscal years beginning after December 15, 2014.
	Development Stage Entity
	In June 2014, the FASB issued ASU No. 2014-10, Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation (“ASU 2014-10”). ASU 2014-10 removes all incremental financial reporting requirements from GAAP for development stage entities, including the removal of Topic 915 from the FASB Accounting Standards Codification (“ASC”). In addition, the update adds an example disclosure in Risks and Uncertainties, ASC Topic 275, to illustrate one way that an entity that has not begun planned principal operations could provide information about the risks and uncertainties related to the company’s current activities and removes an exception provided to development stage entities in Consolidations, ASC Topic 810, for determining whether an entity is a variable interest entity—which may change the consolidation analysis, consolidation decision, and disclosure requirements for a company that has an interest in a company in the development stage. ASU 2014-10 is effective for fiscal years beginning after December 15, 2014 with the revised consolidation standards effective for fiscal years beginning after December 15, 2016. Early adoption is permitted. The Company early adopted the guidance and eliminated the presentation and disclosure requirements of ASC Topic 915 during the three months ending June 30, 2014.

Business_Agreements

Business Agreements	9 Months Ended
	Sep. 30, 2014
Business Agreements	'
Business Agreements	'
	4.Business Agreements
	Ranbaxy Laboratories
	In January 2014, the Company and Ranbaxy Laboratories Limited (“Ranbaxy”) executed a royalty-bearing and non-transferrable license agreement (“License Agreement”) for BOW015 to Ranbaxy for a broad range of territories including India, selected Southeast Asian markets and North Africa. Under the terms of the agreement, the Company and Ranbaxy will pursue the commercialization of BOW015 in India and Ranbaxy received the right to sell BOW015 in the territories specified in the agreement. Ranbaxy does not have the right to manufacture BOW015.
	Ranbaxy made an upfront payment of $500 upon the execution of the agreement and is obligated to pay the Company up to $1,000 if certain development and regulatory approval milestones are achieved and up to $10,000 if certain sales milestones are achieved. Additionally, the Company is entitled to receive royalties in the mid-teens on net sales in the territories, which royalties are subject to reduction or renegotiation in certain limited circumstances. Half of the upfront payment and certain development and regulatory milestones may be refundable to Ranbaxy in certain circumstances if the Company does not complete certain specified requirements.
	Unless terminated earlier in accordance with the terms of the agreement, the license agreement with Ranbaxy expires 20 years following the first commercial sale in the territories.
	Under the agreement, Ranbaxy is responsible for all activities related to the commercialization of BOW015 in the territories. The Company is responsible for performing the development activities required for obtaining regulatory approval in India, joint steering committee participation and clinical and commercial supply of product. The Company also agreed to perform the development activities required to obtain regulatory approval in other parts of the territories. These activities and the related fees will be agreed upon by Ranbaxy and the Company in future written agreements.
	The Company has determined that the deliverables under the Ranbaxy agreement are the license, development activities related to regulatory approval in India, joint steering committee services and the obligation to supply clinical and commercial product. The Company’s obligation to perform future development activities to obtain regulatory approval in other parts of the territories is not a deliverable at the inception of the agreement as the Company will be compensated separately for these activities, and it is uncertain at this time if the Company will ever be requested to perform these activities by Ranbaxy.
	The Company determined that, the license and the other activities and services do not have standalone value apart from the requirement for the Company to deliver commercial material. Ranbaxy has not been granted a license to manufacture BOW015, which prevents them from using the license and related services for their intended purpose without the involvement of the Company. Therefore, the deliverables are not separable and represent one single unit of accounting. When multiple deliverables are accounted for as a single unit of accounting, the Company bases its revenue recognition pattern on the last to be provided deliverable. As a result, no revenue will be recognized until delivery of the commercial supply begins. All amounts received from Ranbaxy have been recorded as deferred revenue as of September 30, 2014. Once such delivery begins, the deferred revenue amounts will be recognized as revenue over the remaining term of the Supply Agreement.
	The arrangement includes the delivery of commercial material and therefore does not qualify for the milestone method of revenue recognition as the agreement is not a research and development arrangement. As a result, upon achievement of a milestone, the amounts will be included in the total arrangement consideration. In January 2014, the Company invoiced Ranbaxy $125 related to the filing for approval in India. In March 2014, the Drug Controller General in India approved BOW015 for commercial sale to the Indian market, upon which a payment from Ranbaxy of $250 became due and payable and was invoiced in April 2014. In September 2014, the Company executed a supply agreement with Ranbaxy, upon which an additional milestone payment of $125 became due. The Company has invoiced Ranbaxy for a total of $1,000, including the upfront payment, and received payments related to the agreement totaling $1,000 during the nine months ended September 30, 2014.
	On September 9, 2014, the Company entered into an amendment (the “Amendment”) to the License Agreement. The Amendment amended the License Agreement to revise (i) the royalty tiers for net sales based on final product sale forecasts and supply costs in the territory, and (ii) Ranbaxy’s obligations with respect to minimum annual sales targets in any given country such that the obligations are subject to a final grant of approval for BOW015 by the applicable regulatory authority for all indications as have been granted for the innovator product in such country. Other than as set forth in the Amendment, the License Agreement remains in full force and effect following the parties’ execution of the Amendment.
	In September 2014, the Company and Ranbaxy entered into a supply agreement for BOW015 under which Epirus, through its third party manufacturing supplier, will provide Ranbaxy with finished products for clinical use, regulatory use and commercialization in accordance with the License Agreement. Under the terms of the supply agreement, the Company’s designated manufacturer will receive consideration from Ranbaxy for commercial finished product. Unless terminated earlier in accordance with terms, the Company’s supply agreement with Ranbaxy expires 10 years from the effective date, subject to five two-year automatic renewal periods.
	Orygen Biotechnology
	In September 2013, the Company entered into a binding Heads of Agreement (“Orygen Heads of Agreement”) with Orygen Biotechnology (“Orygen”), a Brazilian corporation, for the negotiation of the terms of a definitive agreement under which Orygen would be granted exclusive rights to commercialize BOW015 in Brazil. As consideration for entry into the Orygen Heads of Agreement, and the rights to be granted under the definitive agreement, the Company received a non-creditable, non-refundable initial upfront cash payment of $250 from Orygen.
	The Orygen Heads of Agreement, as extended by the parties, was terminated on May 19, 2014. The Company recognized the $250 upfront cash payment as other income in the condensed consolidated statement of operations and comprehensive loss in the nine months ended September 30, 2014.
	Livzon Mabpharm
	In September 2014, the Company entered into an Exclusive License and Collaboration Agreement (the “Agreement”) with Livzon Mabpharm Inc. (“Livzon”) for the global development and commercialization of certain antibodies or related biological compounds, including the Company’s BOW015, a biosimilar version of infliximab.
	Under the Agreement, the Company and Livzon each granted the other party, in the other party’s territory, exclusive, royalty-bearing licenses under certain patent rights and know-how to develop, manufacture and commercialize BOW015 and up to four additional compounds chosen by mutual agreement of the parties (collectively, the “Collaboration Compounds”). Livzon’s territory consists of China, Hong Kong, Macau and Taiwan (the “Livzon Territory”), and the Company’s territory consists of the rest of the world.  The parties share pre-clinical development expenses for each Collaboration Compound based on certain factors specific to each compound. Each party bears the responsibility and expenses for clinical development and commercialization of each Collaboration Compound in its territory. Livzon will be the preferred supplier of each Collaboration Compound for pre-clinical, clinical, and commercialization purposes, subject to Livzon’s satisfaction of certain performance criteria.
	As consideration for the license granted to Livzon to develop and commercialize BOW015, the Company is eligible to receive from Livzon a milestone payment of $2,500 upon the achievement of a specified regulatory milestone in the Livzon Territory. The Company is also eligible to receive from Livzon tiered royalties based on a percentage of net sales of BOW015 products in the Livzon Territory ranging from the low- to high-single digits. Any future Collaboration Compounds have cross-milestone and royalty obligations in amounts to be mutually agreed upon at a later date.
	If not terminated earlier or extended by mutual agreement of the parties, the Agreement expires in its entirety 20 years from the effective date.
	Moksha8 Pharmaceuticals
	In September 2014, the Company entered into an amendment (the “Amendment”) to that certain Revenue and Negotiation Rights Agreement between the Company and Moksha8 Pharmaceuticals, Inc. (“Moksha8”), dated as of December 31, 2010 (the “Moksha8 Revenue Agreement”). Under the terms of the Moksha8 Revenue Agreement, the Company was required to pay to Moksha8 royalties based on nets sales of BOW015 by the Company or its affiliates at a percentage in the very low double digits, and a portion of all licensing revenue received by the Company from third parties to commercialize BOW015 at a percentage in the mid-teens, subject in each case to reduction in certain circumstances.
	The Amendment amends the Moksha8 Revenue Agreement to terminate the Company’s revenue sharing payment obligations with respect to products that are biosimilars to infliximab, which includes the Company’s BOW015 product, in exchange for the Company’s payment of $1,500 in two installments.
	In October 2014, the Company entered into a second amendment (the “Second Amendment”) to the Amendment between the Company and Moksha8. Under the terms of the Second Amendment, the $1,500 of payments described in the Amendment was reduced to $1,400. As of September 30, 2014, no payments were made by the Company to Moksha8 and the Company recorded an accrued liability of $1,400, an extinguishment of previously accrued royalty obligations of $150 and an intangible asset of $1,250 (Note 6). Pursuant to the Amendment and the Second Amendment, in October 2014, the Company made payments to Moksha8 totaling $1,400.
	Moksha8 is owned in part by Montreaux Equity Partners and TPG Capital, which are also shareholders of the Company. As of September 30, 2014, Montreaux Equity Partners and TPG Capital each own approximately 17% of the Company. TPG Capital is a legal affiliate of the Company.

Merger

Merger	9 Months Ended
	Sep. 30, 2014
Merger	'
Merger	'
	5.Merger
	As described in Note 1, “Organization,” on July 15, 2014, the Company completed the Merger with Zalicus.  Pursuant to the Merger Agreement, each share of capital stock of Private Epirus was exchanged for 0.13259 shares of Public Epirus Common Stock (the “Exchange Ratio”). All Private Epirus stock options granted under the Private Epirus stock option plans (whether or not then exercisable) that were outstanding prior to the effective time of the Merger, and all warrants to purchase Private Epirus capital stock that were outstanding prior to the effective time of the Merger were exchanged at the same ratio as described below. Upon the consummation of the Merger, equity holders of Private Epirus were issued an aggregate of 10,288,180 shares of Public Epirus Common Stock, plus 1,152,042 and 21,996 shares of Public Epirus Common Stock which could be issued in the future upon exercise of stock options and warrants, respectively.
	All Private Epirus stock options granted under the Private Epirus stock option plans (whether or not then exercisable) that were outstanding prior to the effective time of the Merger and all warrants to purchase Private Epirus capital stock that were outstanding prior to the effective time of the merger were exchanged for options to purchase Public Epirus Common Stock or warrants to purchase Public Epirus Common Stock, as applicable. After the Effective Time, all outstanding and unexercised Private Epirus stock options assumed by Zalicus may be exercised solely for shares of Public Epirus Common Stock and all outstanding and unexercised warrants to purchase Private Epirus capital stock may be exercised solely for shares of Public Epirus Common Stock. The number of shares of Public Epirus Common Stock subject to each Private Epirus stock option or warrant assumed by Zalicus was determined by multiplying (a) the number of shares of Private Epirus common stock that were subject to such Private Epirus stock option or warrant, as in effect immediately prior to the Effective Time, by (b) the exchange ratio, as defined in the merger agreement, and rounding the resulting number down to the nearest whole number of shares of Public Epirus Common Stock. The per share exercise price for the Public Epirus Common Stock issuable upon exercise of each Private Epirus stock option or warrant assumed by Zalicus was determined by dividing (a) the per share exercise price of Private Epirus common stock subject to such Private Epirus stock option or warrant, as in effect immediately prior to the Effective Time, by (b) the Exchange Ratio and rounding the resulting exercise price up to the nearest whole cent.
	All Zalicus equity awards granted prior to the Merger remained legally outstanding.
	The Merger has been accounted for as a reverse acquisition under the acquisition method of accounting with Private Epirus treated as the accounting acquirer and Zalicus treated as the acquired company for financial reporting purposes. Private Epirus was determined to be the accounting acquirer based upon the terms of the Merger and other factors, such as relative voting rights and the composition of the combined company’s board of directors and senior management. Accordingly, the Zalicus tangible and identifiable intangible assets acquired and liabilities assumed were recorded at fair value as of the date of acquisition, with the excess consideration transferred recorded as goodwill.
	See Note 12, “Stock-Based Compensation,” for additional details regarding the accounting treatment for the equity awards of Private Epirus and Zalicus.
	The acquisition-date fair value of the consideration transferred is as follows:
	Number of shares of Public Epirus Common Stock owned by Zalicus stockholders (1)		2,635,871
	Multiplied by the price per share of Public Epirus Common Stock (2)		$	11.80
	Fair value of shares of Public Epirus Common Stock owned by Zalicus stockholders		$	31,104
	Acquisition-date fair value of assumed Zalicus equity awards attributable to precombination services (3)		$	220
	Total consideration transferred		$	31,324
		(1) The stock transferred in the table above is comprised of 2,610,871 common shares outstanding at the time of the Merger plus 25,000 restricted stock units (RSUs) that vested immediately upon the closing of the Merger. The fair value of shares of Public Epirus Common Stock owned by Zalicus shareholders of $31,104 includes approximately $1 related to fractional shares resulting from the Reverse Stock Split.
		(2) The shares outstanding are multiplied by the closing trading price of Public Epirus Common Stock as of the Merger date.
		(3) Consideration transferred includes approximately $220 of Zalicus equity awards assumed and deemed attributable to precombination services to Zalicus. This amount excludes approximately $355 of acquisition-date fair value attributable to postcombination service, which was recorded to reflect the acceleration of nonvested equity awards of Zalicus upon the termination of certain Zalicus employees after the Merger. The Company recognized the $355 as stock-based compensation expense in the postcombination period ended September 30, 2014 (Note 12). The fair value of the equity awards at July 15, 2014 was determined using a Black-Scholes option-pricing model with the following ranges of assumptions: exercise price of $14.70 per share to $591.00 per share; underlying stock value of $11.80 per share; expected volatility of 66.02%; expected term of 0.1 years to 6.0 years; and risk-free interest rate of 1.91%.
	The following table summarizes the estimated fair values of the assets acquired and liabilities assumed at the date of acquisition:
			July 15, 2014
	Cash and cash equivalents		$	13,756
	In-process research and development		5,500
	Goodwill		14,864
	Restricted cash		1,850
	Other assets		253
	Total assets acquired		36,223
	Accounts payable		(1,584		)
	Accrued expenses and other current liabilities		(757		)
	Other liabilities		(391		)
	Deferred tax liabilities		(2,166		)
	Total liabilities assumed		(4,899		)
	Total net assets acquired		$	31,324
	The purchase price allocation has been prepared on a preliminary basis and is subject to change as additional information becomes available concerning the fair value and tax basis of the assets acquired and the liabilities assumed. Any adjustments to the purchase price allocation will be made as soon as practicable but no later than one year from July 15, 2014, the acquisition date.
	For acquired working capital accounts such as accounts receivable, prepaid expenses and other current assets, accounts payable and certain accrued expenses, the Company determined that no fair value adjustments were required due to the short timeframe until settlement for these assets and liabilities.
	The fair value of the IPR&D was determined using the multi-period excess earnings method, a variation of the income approach, including a discount rate of 13.1% applied to the projected cash flows. The Company believes the assumptions used are consistent and representative of those a market participant would use in estimating the fair value of the IPR&D. The Company will not begin amortizing the IPR&D asset until the research and development is complete and the asset is reclassified to a definite-lived amortizing asset.
	Goodwill is calculated as the difference between the acquisition-date fair value of the consideration transferred and the fair values of the assets acquired and liabilities assumed. The goodwill is not expected to be deductible for income tax purposes. Goodwill is recorded as an indefinite-lived asset and is not amortized but tested for impairment on an annual basis or when indications of impairment exist.
	Other liabilities of $391 plus $376 out of the $757 of accrued expenses and other liabilities relates to a sublease liability assumed for Zalicus’ Cambridge, Massachusetts facility. The liability represents the fair value of the difference between the total sublease payments and the total payments for the facility per the lease agreement. The original lease and the sublease agreement terminate in January 2017.
	The deferred tax liability of $2,166 relates to the temporary difference associated with the $5,500 value of the IPR&D asset, which is not deductible for tax purposes. The deferred tax liability was recorded based on a 39.39% effective tax rate.
	The operating results of Zalicus for the period from July 16, 2014 to September 30, 2014, including an operating loss of $25, have been included in the Company’s condensed consolidated financial statements as of and for the three and nine months ended September 30, 2014.
	The Company incurred a total of $5,665 in transaction costs in connection with the Merger, excluding Zalicus transaction costs, which were included in selling, general and administrative expense within the consolidated statements of income for the nine months ended September 30, 2014.  The following supplemental unaudited pro forma information presents the Company’s financial results as if the acquisition of Zalicus had occurred on January 1, 2013:
			Nine Months Ended
			September 30,
			2014			2013
	Total revenues, net		$	2,735		$	14,731
	Net loss		(22,025		)	(61,727		)
	The above unaudited pro forma information was determined based on the historical GAAP results of the Company and Zalicus. The unaudited pro forma consolidated results are not necessarily indicative of what the Company’s consolidated results of operations actually would have been if the acquisition was completed on January 1, 2013. The unaudited pro forma consolidated net loss includes pro forma adjustments primarily relating to the following non-recurring items directly attributable to the business combination:
		(1) Elimination of $8,559 of transaction costs for both the Company and Zalicus from the nine months ended September 30, 2014, and inclusion of these transaction costs in the nine months ended September 30, 2013;
		(2) Elimination of $355 of stock-based compensation expense related to the acceleration of vesting of previously unvested Zalicus awards in connection with the Merger from the nine months ended September 30, 2014, and inclusion of this charge in the nine months ended September 30, 2013;
		(3) Elimination of $1,980 of expense related to severance agreements from the nine months ended September 30, 2014, and inclusion of this charge in the nine months ended September 30, 2013; and
		(4) Elimination of $222 and $805 of other expense related to the change in the fair values of liability-classified warrants from the nine months ended September 30, 2014 and 2013, respectively, as the Company’s outstanding warrants were reclassified to equity in connection with their exchange in the Merger.

Goodwill_IPRD_and_Intangible_A

Goodwill, IPR&D and Intangible Assets, Net	9 Months Ended
	Sep. 30, 2014
Goodwill, IPR&D and Intangible Assets, Net	'
Goodwill, IPR&D and Intangible Assets, Net	'
	6.Goodwill, IPR&D and Intangible Assets, Net
	The following table represents changes in goodwill for the nine months ended September 30, 2014:
	Balance at December 31, 2013	$	1,499
	Goodwill related to Merger	14,864
	Balance at September 30, 2014	$	16,363
	As of September 30, 2014, there were no accumulated impairment losses. Goodwill has been assigned to the Company’s single reporting unit, which is the single operating segment by which the chief decision maker manages the Company.
	IPR&D of $5,500 was recognized in connection with the Merger.  See Note 5, “Merger,” for additional details.
	In July 2014, upon receipt of the necessary approvals to manufacture and market BOW015 in India, the Company reclassified the $2,437 of IPR&D associated with its lead product BOW015 from an indefinite-lived asset to a finite-lived asset. During the three months ended September 30, 2014, the Company began amortizing the intangible asset over its expected useful life of approximately 16.5 years. The Company determined the useful life of the asset based upon the period over which the Company expects to earn future economic benefit for BOW015. The Company recognizes amortization expense utilizing the straight-line method.
	As described in Note 4, “Business Agreements,” in September 2014 and October 2014, the Company entered into the Amendment and Second Amendment, respectively, which amended the Moksha8 Revenue Agreement to terminate the Company’s revenue sharing payment obligations with respect to products that are biosimilars to infliximab, in exchange for payments of $1,400. In connection with the payments under the Amendment and Second Amendment, in September 2014, the Company recorded an intangible asset of $1,250, which will be amortized over the expected useful life of the intangible asset associated with BOW015, described above.
	Intangible assets, net of accumulated amortization is as follows:
		September 30, 2014			December 31, 2013
	Intangible assets	$	3,687		$	—
		3,687			—
	Less: accumulated amortization—intangible assets	(26		)	—
	Intangible assets, net	$	3,661		$	—
	Amortization expense, which is included within research and development expense in the condensed consolidated statements of operations and comprehensive loss, was $26 and $0 for the nine months ended September 30, 2014 and 2013, respectively.
	The estimated aggregate amortization of intangible assets as of September 30, 2014, for each of the five succeeding years and thereafter is as follows:
		September 30, 2014
	Remainder of 2014	$	56
	2015	225
	2016	225
	2017	225
	2018	225
	2019 and thereafter	2,705
	Total	$	3,661

Accrued_Expenses_and_Other_Cur

Accrued Expenses and Other Current Liabilities	9 Months Ended
	Sep. 30, 2014
Accrued Expenses and Other Current Liabilities	'
Accrued Expenses and Other Current Liabilities	'
	7.Accrued Expenses and Other Current Liabilities
	Accrued expenses consisted of the following:
		September 30, 2014		December 31, 2013
	Accrued professional fees	$	1,034	$	544
	Accrued compensation	1,004		725
	Accrued manufacturing expense	603		380
	Accrued clinical expense	455		286
	Accrued royalty settlement	1,400		—
	Accrued interest expense	—		502
	Other	130		55
	Total accrued expenses	$	4,626	$	2,492

Convertible_Debt

Convertible Debt	9 Months Ended
	Sep. 30, 2014
Convertible Debt	'
Convertible Debt	'
	8.Debt
	2013 Notes
	On March 10, 2014, the $12,500 principal amount of convertible notes outstanding at December 31, 2013, plus accrued but unpaid interest of $684, was converted into 13,184,383 shares of Series A convertible preferred stock (“Series A Preferred”).
	March 2014 Notes
	On March 10, 2014, the Company issued and sold $5,000 of convertible notes to finance the operations of the Company. The notes bore interest at a rate of 8% per annum, had a maturity date of April 30, 2014 and provided the holders of the notes with 20% warrant coverage.
	The 2014 note agreements contained the following settlement provisions: (1) in the event of a qualified financing in which the Company issues and sells shares of preferred stock for gross proceeds of at least $20,000 from one or more persons that are not current holders of capital stock, prior to the maturity date of the note, all outstanding principal and accrued interest automatically converts into the same class and series of capital stock at the price paid per share by the other purchasers in the qualified financing event; (2) in the event of a corporate merger, all outstanding principal and accrued interest automatically converts into the Company’s Series A Preferred at a conversion price equal to $1.00 per share; (3) in the event of an acquisition or asset transfer, the Company shall pay the outstanding note holders an amount in cash accrued and unpaid interest through the date of the payment and three times the outstanding principal balance; (4) in the event of a non-qualified financing, holders of the notes shall have the option to either convert all outstanding principal and any accrued but unpaid interest into shares of the same class and series of capital stock at the conversion price equal to the price per share of the non-qualified financing securities, or into shares of Series A Preferred, at a conversion price equal to $1.00 per share; (5) following the maturity date of the note, upon a written election by a majority of note holders, all outstanding principal and accrued interest converts into Series A Preferred; and (6) in the event of a default, all outstanding principal and accrued interest becomes immediately due and payable without notice or demand. The warrants were immediately exercisable into 1,000,000 shares of Series A Preferred at an exercise price of $0.01 per share. In the event of a qualified financing, the warrants become exercisable into a number of shares of the preferred stock issued in the qualified financing that represents $1,000 divided by the price per share of the preferred stock.
	The provisions requiring conversion or prepayments of the 2014 notes upon a qualified financing, a corporate merger, an acquisition or asset transfer, or an event of default constituted an embedded compound derivative that is being accounted for separately. The Company determined that the fair value of this embedded compound derivative upon the issuance of the 2014 notes was $23, which was subtracted from the original carrying amount of the 2014 notes and reflected as a debt discount, and also increased liabilities by $23. As of March 31, 2014, the liability was accounted for at fair value, with changes in fair value recognized as other income (expense) in the statement of operations and comprehensive loss. As of March 31, 2014, the fair value of the embedded derivative was $23 and the Company did not record a gain or loss in the accompanying statements of operations and comprehensive loss for the three months ended March 31, 2014.
	The Company determined the 2014 notes contained a beneficial conversion feature (“BCF”) measured at $2,071, which was recorded as a discount to the convertible notes.
	The aggregate fair value of the warrants at their issuance date was $1,171, which was also recorded as a discount to the convertible notes.
	The total debt discount resulting from the embedded compound derivative, BCF, warrants and lender fees is being amortized as interest expense using the effective interest method over the period between the convertible notes’ issuance and maturity date.
	On April 15, 2014, upon the closing of a qualified financing, the issuance of Series B convertible preferred stock (“Series B Preferred”) (Note 11), the $5,000 principal amount of convertible notes issued in March 2014, plus accrued and unpaid interest of $13, were converted into 3,947,363 shares of Series B Preferred and the warrants became exercisable into 787,402 shares of Series B Preferred at an exercise price per share of $0.01.
	The conversion of the notes into Series B Preferred was accounted for as an extinguishment of the notes and a repurchase of the BCF. In accordance with the accounting guidance for extinguishments of convertible debt with embedded BCFs, the Company recorded a reduction of additional paid-in capital of $1,150, which represents the intrinsic value of the BCF at the time of extinguishment, and a gain on the extinguishment of the notes of $22 during the nine months ended September 30, 2014, which represents the difference between the net carrying value of the notes at the time of extinguishment in excess of the remainder of the consideration transferred after the $1,150 allocated to the repurchase of the BCF, plus the derecognition of the $23 derivative liability. Consideration transferred was $5,013, which is the fair value of the shares of Series B Preferred into which the notes converted. The gain was recorded to other income (expense) within the condensed consolidated statement of operations and comprehensive loss.
	Hercules Notes
	On September 30, 2014, the Company entered into a Loan and Security Agreement (the “Loan Agreement”) with Hercules Technology Growth Capital, Inc. (“Hercules”). Under the Loan Agreement, Hercules will provide the Company with access to two term loans with an aggregate principal amount of up to $15,000. The first term loan, of a principal amount of $7,500, was funded on October 1, 2014, and is repayable in monthly installments until April 1, 2018, including an initial interest-only period of 18 months after closing. The second term loan, of a principal amount of up to $7,500, can be drawn down at the Company’s option at any time between September 30, 2014 and May 30, 2015, and interest and principal is repayable upon the same schedule as the repayment for the first term loan, including the same interest-only period. The interest-only period for both term loans may be extended at the Company’s request to November 1, 2016 contingent upon the Company’s first patient being dosed in a pivotal clinical study of BOW015 (infliximab) for approval in the European Union prior to May 1, 2016. The Company may elect to pay, in whole or in part, any regularly scheduled installment of principal up to an aggregate maximum amount of $2,000 by converting a portion of the principal into shares of the Company’s common stock at a rate of $8.06, but only if the Company’s stock is trading at a level greater than the exercise price for seven consecutive trading days and the shares to be issued do not exceed 15% of the Company’s total trading volume for the previous 22 consecutive trading days. The Company may prepay all or part of the term loans at its election, provided that it will be required to pay a prepayment fee equal to 2.00% of the amount prepaid, if prepaid in the first 18 months following closing. If the Company prepays all or part of the term loans 18 months or later following closing, there is no prepayment fee. The Company will be required to pay a fee of 3.00% of the aggregate original principal amount at the earliest to occur of; loan maturity date, the date the Company prepays the outstanding obligations or the date the obligations become due and payable upon acceleration. As a security interest, the Company is obligated to collateralize all available receivables, equipment, fixtures, intangibles, inventory, deposit accounts and cash of the Company, other than the Company’s intellectual property.
	Pursuant to the Loan Agreement, Hercules was granted the right to participate, in an amount of up to $1,000, in subsequent private placements of the Company’s equity securities.
	In connection with the Loan Agreement, on September 30, 2014, the Company issued to Hercules a warrant to purchase 64,194 shares of Public Epirus Common Stock at an exercise price of $7.01 per share. See Note 9, “Warrants,” for further description of the warrant.

Warrants

Warrants	9 Months Ended
	Sep. 30, 2014
Warrants	'
Warrants	'
	9.Warrants
	In March 2014, the Company issued warrants, in connection with a convertible notes issuance, to purchase 1,000,000 shares of Series A Preferred with an exercise price of $0.01 per share (Note 8). Upon the Series B Preferred financing described in Notes 8 and 11, these warrants became exercisable into 787,402 shares of Series B Preferred at an exercise price of $0.01 per share. The aggregate fair value of such warrants at their issuance date was $1,171. Each warrant was immediately exercisable and expires approximately seven years from the original date of issuance. Each warrant was exercisable on either a physical settlement or net share settlement basis.
	In April 2014, warrants to purchase 5,101,816 shares Series A Preferred were exercised into 5,101,816 shares of Series A Preferred. In April 2014, the warrants to purchase Series B Preferred were exercised into 787,402 shares of Series B Preferred.
	In connection with the Merger on July 15, 2014, all of the Company’s outstanding warrants exercisable for shares of preferred stock were exchanged for warrants exercisable for shares of Public Epirus Common Stock, which resulted in the reclassification of the liability-classified warrants to additional paid-in capital.
	See Note 10, “Fair Value Measurements,” for additional details.
	As described in Note 8, the Company entered into a Loan Agreement with Hercules under which the Company was given access to up to $15,000 of term loans. As consideration for the Loan Agreement, the Company issued Hercules a five-year warrant to purchase 64,194 shares of its common stock at an exercise price of $7.01 per share (the “Warrant”). The Warrant’s fair value of $248 at September 30, 2014 was determined using a Black-Scholes option-pricing model with the following assumptions: expected volatility of 61.68%; contractual term of five years; and risk-free interest rate of 1.78%. The fair value of the common stock warrants was recorded to prepaid expenses and other current assets and credited to additional paid-in capital upon their issuance on September 30, 2014. In October 2014, upon issuance and recognition of the Hercules notes, the other current asset will be reclassified to a debt discount.
	As of September 30, 2014, all of the Company’s outstanding warrants were classified in equity. As of September 30, 2014, the following warrants to purchase common stock were outstanding:
		As of September 30, 2014
		Number of
		Shares	Exercise
		Underlying	Price
		Warrant	Per Share
	Common Stock	20,953	$	7.55
	Common Stock	1,043	$	0.08
	Common Stock	64,194	$	7.01
	As of December 31, 2013, the following liability-classified warrants to purchase preferred stock were outstanding:
		As of December 31, 2013
		Number of
		Shares	Exercise		Fair Value at
		Underlying	Price		December 31,
		Warrant	Per Share		2013
	Series A Preferred	462,399	$	1.00	$	311
	Series A Preferred	4,805,327	$	0.01	$	5,532

Fair_Value_Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2014
Fair Value Measurements	'
Fair Value Measurements	'
	10.Fair Value Measurements
	The following table summarizes the financial assets and liabilities measured at fair value on a recurring basis in the accompanying balance sheets as of September 30, 2014 and December 31, 2013:
		As of September 30, 2014
		Level 1			Level 2		Level 3		Total
	Assets
	Cash and cash equivalents	$	23,681		$	—	$	—	$	23,681
		$	23,681		$	—	$	—	$	23,681
		As of December 31, 2013
		Level 1			Level 2		Level 3		Total
	Assets
	Cash and cash equivalents	$	1,798		$	—			$	1,798
		$	1,798		$	—	$	—	$	1,798
	Liabilities
	Warrant liability	$	—		$	—	$	5,843	$	5,843
		$	—		$	—	$	5,843	$	5,843
	As of September 30, 2014, the Company did not have any liabilities measured at fair value on a recurring basis.
	Warrant Liability
	The warrant liability represented the liability for warrants to purchase shares of Series A Preferred issued to investors in connection with the Company’s Series A Preferred financings and issued to holders of the Company’s convertible notes. The warrant liability was calculated using the Black-Scholes option-pricing model. This valuation method used inputs such as fair value of the Company’s Series A Preferred and Series B Preferred shares, historical volatility, the term of the warrant and risk-free interest rates. At June 30, 2014, April 15, 2014, March 31, 2014 and December 31, 2013, the fair value of the Series A Preferred and Series B Preferred were determined using a hybrid of the probability-weighted expected return method (“PWERM”) and the option-pricing method (“OPM”) (“Hybrid Method”). At September 30, 2014, the Company did not have any warrants classified as liabilities.
	The PWERM is a scenario-based analysis that estimates the value per share based on the probability-weighted present value of expected future investment returns, considering each of the possible outcomes available to us, as well as the economic and control rights of each share class. Under the OPM, shares are valued by creating a series of call options with exercise prices based on the liquidation preferences and conversion terms of each equity class. The values of the preferred and common stock are inferred by analyzing these options.
	The hybrid method is a hybrid between the PWERM and the OPM, estimating the probability-weighted value across multiple scenarios but using the OPM to estimate the allocation of value within one of or more of those scenarios. In this valuation the hybrid model considers two possible outcomes: (1) an initial public offering (“IPO”) or a reverse merger scenario and (2) continued operations as a private company scenario, which is modelled using the OPM.
	For the IPO or reverse merger scenario, equity value was estimated using the guideline public company (“GPC”) method under the market approach and the discounted cash flow (“DCF”) method under the income approach. Under the GPC method, equity value was estimated as a multiple of paid-in capital, using the median multiple indicated by selected initial public offerings by biotechnology companies. For the DCF method used in the April 15, 2014, March 31, 2014 and December 31, 2013 valuation, a discount rate of 22%, 30% and 35%, respectively, was assumed.
	In the OPM, equity value was estimated by back-solving the overall hybrid value such that the result is equal to the anticipated price of a future preferred stock series. The OPM used in the March 31, 2014 and December 31, 2013 valuation assumed 2.53 and 2.75 years to liquidity, respectively, and annual volatility of 58% and 53%, respectively.
	In the OPM analysis as of April 15, 2014, equity value was estimated by back-solving the overall hybrid value to the actual price per share of Series B Preferred paid in the issuance on April 15, 2014. The OPM used in the April 15, 2014 valuation assumed 2.46 years to liquidity and annual volatility of 59%.
	For the valuation analysis as of June 30, 2014, equity value under the IPO scenario was calculated based on the actual terms of the Merger, as described in Note 1, “Organization,” and Note 5, “Merger,” and the closing trading price per share of Zalicus common stock as of June 30, 2014. In the OPM analysis as of June 30, 2014, equity value was estimated using by back-solving the overall equity value to the actual price per share of Series B Preferred paid in the issuance on April 15, 2014. The OPM used in the June 30, 2014 valuation assumed 2.25 years to liquidity and annual volatility of 59%.
	In connection with the Merger on July 15, 2014, all of the Company’s outstanding warrants exercisable for shares of preferred stock were exchanged for warrants exercisable for shares of Public Epirus Common Stock, which resulted in the reclassification of the liability-classified warrants to additional paid-in-capital. As of July 15, 2014, immediately prior to their exchange and reclassification, all of the Company’s outstanding warrants were remeasured at fair value with the increase in the fair value recorded to other expense in the condensed consolidated statement of operations and comprehensive loss. The fair value of such warrants of $167 at July 15, 2014 was determined using a Black-Scholes option-pricing model with the following ranges of assumptions: exercise price of $0.08 per share to $7.55 per share; underlying stock value of $11.80 per share; expected volatility of 61.58% to 64.96%; contractual term of 3.53 years to 5.10 years; and risk-free interest rate of 1.34% to 1.70%. As of September 30, 2014, the Company does not have any warrants measured using Level 3 inputs.
	Changes in the fair value of the warrant liability where fair value is determined using Level 3 inputs, were as follows:
		September 30, 2014
	Balance at December 31, 2013	$	5,843
	Warrant issuance	1,171
	Change in fair value	222
	Warrant exercises	(7,069		)
	Reclassification to equity	(167		)
	Balance at September 30, 2014	$	—
	Embedded Derivative
	On March 10, 2014, the Company issued $5,000 of convertible notes that contained an embedded compound derivative as described in Note 8. The fair value of the embedded compound derivative was calculated using the “with and without” method. This valuation method first values the notes with the embedded compound derivative (“with” scenario) and subsequently values the notes without the embedded compound derivative (“without” scenario). The difference between the fair value of the notes in the “with and without” scenarios is determined to be the fair value of the embedded compound derivative as of the valuation date.
	Accordingly, the valuation of the embedded compound derivative was determined using Level 3 inputs.
	Changes in the fair value of the embedded compound derivative where fair value is determined using Level 3 inputs, were as follows:
		September 30, 2014
	Balance at December 31, 2013	$	—
	Embedded compound derivative	23
	Change in fair value	—
	Derecognition of embedded compound derivative	(23		)
	Balance at September 30, 2014	$	—
	The following table provides quantitative information about the fair value measurements, including the range of assumptions for the significant unobservable inputs used in the hybrid method valuations of the warrant liability and “with and without” method used for the embedded compound derivative:
		Valuation Assumptions as of
		June 30, 2014		April 15, 2014		March 31, 2014	March 10, 2014
	Hybrid approach
	Discount rate	*		21% to 30%		25% to 30%	25% to 30%
	Probability weighted value for common stock	20% to 80%		30% to 70%		45% to 55%	45% to 55%
	Discount for lack of marketability	5% to 30%		11% to 34%		10% to 28%	10% to 28%
	With and Without approach
	Probability of occurrence of certain events	**		0% to 100%		5% to 50%	5% to 50%
	Market yield	**		25%		25%	25%
	Recovery rate	**		31% to 47%		31% to 47%	31% to 47%
	* Discount rate not used as DCF was not calculated.
	** No compound derivative to fair value at June 30, 2014.
	Significant increases (decreases) in the significant unobservable inputs used in the fair value measurement of the warrant liability and the embedded compound derivative in isolation would result in significantly higher (lower) fair value measurements.

Convertible_Preferred_Stock

Convertible Preferred Stock	9 Months Ended
	Sep. 30, 2014
Convertible Preferred Stock	'
Convertible Preferred Stock	'
	11.Convertible Preferred Stock
	In April 2014, Epirus closed an initial Series B Preferred financing with an issuance of 24,409,444 shares for aggregate proceeds of approximately $31,000. Upon the closing of such financing, the $5,000 principal amount of convertible notes issued in March 2014, plus accrued and unpaid interest of $13, were converted into 3,947,363 shares of Series B Preferred (Note 8).
	Upon the closing of the Merger, all outstanding shares of preferred stock were exchanged for shares of Public Epirus Common Stock as part of the Merger at the Exchange Ratio.  See Note 5, “Merger,” for additional details. As of September 30, 2014, the Company did not have any convertible preferred stock issued or outstanding.
	Prior to the exchange of preferred stock for Public Epirus Common Stock, the Series A Preferred and Series B Preferred had the following terms:
	Series A Preferred
	Conversion
	Each share of Series A Preferred was convertible at the option of the holder, at any time and from time to time, into fully paid and non-assessable shares of common stock as was determined by dividing the original issuance price by the then applicable conversion price (equal to the original issuance price at all dates Series A Preferred was outstanding).
	Voting Rights
	The holders of Series A Preferred and Series B Preferred were entitled to vote as one class, with common stockholders, based on the number of shares of common stock each holder would receive upon conversion of their Series A Preferred or Series B Preferred into shares of common stock, for all matters except for the approval of certain major actions by the Company and the election of directors. Subject to certain ownership thresholds and approval rights set forth in the Company’s amended and restated certificate of incorporation and an amended and restated voting agreement by and among certain stockholders of the Company, directors were elected as follows: the holders of Series B Preferred voted as a separate class for the election of one director; the holders of Series A Preferred voted as a separate class for the election of three directors; the holders of common stock voted as a separate class for the election of one director, which shall have been the currently serving chief executive officer; and the holders of common stock, and Series A Preferred and Series B Preferred, on an as-converted basis, voted together as a single class for the election of any remaining directors. If the common stock of the Company or any affiliate of the Company was not listed on a national securities exchange or other public trading platform on or prior to October 15, 2014, then the Series B Preferred stockholders would thereafter have been entitled to elect two members of the board of directors.
	Dividends
	Holders of Series A Preferred were entitled to receive, when and if declared by the board of directors, dividends at the rate of 8% of the original issuance price. Series A Preferred dividends were non-cumulative. In addition to the non-cumulative 8% dividend, the Series A Preferred shares would have also received (on an “as-converted” basis) the same dividend as that declared on common stock shares. The order of preference in the event of a dividend distribution, when and if declared by the board of directors, would have been first made to holders of Series B Preferred, then to holders of Series A Preferred and lastly to holders of common stock. No dividends were ever declared or paid.
	Liquidation Rights
	In the event of a voluntary or involuntary liquidation, dissolution, change in control or winding up of the Company, holders of Series A Preferred were entitled to be paid out second, following holders of Series B Preferred, of the assets available at a rate of the original issue price, plus any accrued but unpaid dividends, prior to any payment being made to holders of common stock.
	If the assets of the Company available for distribution to stockholders were insufficient to permit payment of the full amount to which each stockholder is entitled, holders of shares of the Series A Preferred would have shared ratably in any distribution of the remaining assets of the Company in proportion to the respective amounts which would otherwise have been payable under the circumstances in the order of liquidation preference.
	After the payment of the full liquidation preference of the preferred stock, the remaining assets, if any, would have been distributed ratably to the holders of preferred stock and common stock on an as-if-converted to common stock basis provided that if the aggregate amount the holders of the Series A Preferred were entitled to receive exceeded three times the original issue price plus all declared and unpaid dividends thereon (the “Maximum Participation Amount”), such holders would have been entitled to receive the greater of the Maximum Participation Amount or the amount they would have received if all shares of preferred stock had been converted into common stock immediately prior to the liquidation event.
	Because liquidation rights included a change in control, the Series A Preferred was classified within temporary equity. However, since a change in control was not considered probable, no adjustment to the carrying amount was required at any date the Series A Preferred was outstanding.
	Series B Preferred
	Conversion
	Each share of Series B Preferred was convertible at the option of the holder, at any time and from time to time, into fully paid and non-assessable shares of common stock as was determined by dividing the original issuance price by the then applicable conversion price (equal to the original issuance price at all dates Series A Preferred was outstanding).
	Voting Rights
	Holders of Series B Preferred and Series A Preferred were entitled to vote as one class, with common stockholders, based on the number of common stock each holder would receive upon conversion of their Series A or Series B Preferred into shares of common stock, for all matters except for the approval of certain major actions by the Company and the election of directors. Subject to certain ownership thresholds and approval rights set forth in the Company’s amended and restated certificate of incorporation and an amended and restated voting agreement by and among certain stockholders of the Company, directors were elected as follows: the holders of Series B Preferred voted as a separate class for the election of one director; the holders of Series A Preferred voted as a separate class for the election of three directors; the holders of common stock voted as a separate class for the election of one director, which would have been the currently serving chief executive officer; and the holders of common stock, and Series A Preferred and Series B Preferred, on an as-converted basis, voted together as a single class for the election of any remaining directors. If the common stock of the Company or any affiliate of the Company was not listed on a national securities exchange or other public trading platform on or prior to October 15, 2014, then the Series B Preferred stockholders would thereafter have been entitled to elect two members of the board of directors.
	Dividends
	Holders of Series B Preferred were entitled to receive, when and if declared by the board of directors, dividends at the rate of 8% of the original issuance price. Series B Preferred dividends were non-cumulative. In addition to the non-cumulative 8% dividend, the Series B Preferred shares would have also received (on an “as-converted” basis) the same dividend as that declared on common stock shares. The order of preference in the event of a dividend distribution, when and if declared by the board of directors, would have been first made to holders of Series B Preferred, then to holders of Series A Preferred and lastly to holders of common stock. No dividends were ever declared or paid.
	Liquidation Rights
	In the event of a voluntary or involuntary liquidation, dissolution, change in control or winding up of the Company, holders of Series B Preferred were entitled to be paid out first of the assets available at a rate of their original issue price, plus any accrued but unpaid dividends, prior to any payment being made to holders of Series A Preferred or common stock.
	If the assets of the Company available for distribution to stockholders were insufficient to permit payment of the full amount to which each stockholder is entitled, holders of shares of the Series B Preferred would have shared ratably in any distribution of the remaining assets of the Company in proportion to the respective amounts which would otherwise have been payable under the circumstances in the order of liquidation preference.
	After the payment of the full liquidation preference of the preferred stock, the remaining assets, if any, would have been distributed ratably to the holders of preferred stock and common stock on an as-if-converted to common stock basis, provided that if the aggregate amount the holders of the Series B Preferred were entitled to receive exceeded three times the original issue price plus all declared and unpaid dividends thereon (the “Maximum Participation Amount”), such holders would have been entitled to receive the greater of the Maximum Participation Amount or the amount they would have received if all shares of preferred stock had been converted into common stock immediately prior to the liquidation event.
	Because liquidation rights included a change in control, the Series B Preferred was classified within temporary equity. However, since a change in control was not considered probable, no adjustment to the carrying amount was required at any date the Series B Preferred was outstanding.

StockBased_Compensation

Stock-Based Compensation	9 Months Ended
	Sep. 30, 2014
Stock-Based Compensation	'
Stock-Based Compensation	'
	12.Stock-Based Compensation
	In April 2014, the Private Epirus board of directors amended the terms of the 2011 Equity Incentive Plan (“2011 Plan”) to increase the authorized number of shares of common stock available for issuance under the 2011 Plan from 740,470 to 1,504,752.
	In August 2014, the Company submitted a Form S-8 Registration Statement (“S-8”) to the SEC. As reflected in the S-8, the Company amended its 2004 Equity Plan to increase the number of shares available for issuance under the 2004 Plan by 3,000,000 shares of common stock. As of September 30, 2014, the Company had 2,818,071 shares available for issuance.
	For the three and nine months ended September 30, 2014 and 2013, the Company recognized stock-based compensation expense of approximately $943, $1,314, $35 and $93, respectively, in connection with its stock-based payment awards. Stock-based compensation expense for the three and nine months ended September 30, 2014 includes $355 of postcombination stock-based compensation expense resulting from the acceleration of vesting of previously unvested Zalicus stock options and RSUs, which occurred upon the termination of certain Zalicus employees following the Merger, and $185 and $283, respectively, related to restricted stock issued to a non-employee.
	As described in Note 5, through the Merger, outstanding Zalicus equity awards remained legally outstanding without change to any agreement terms. Such Zalicus equity awards were assumed to have been exchanged for equity awards of the Company, the accounting acquirer. As a result, the portion of the acquisition-date fair value of the Zalicus equity awards attributable to precombination service to Zalicus, $220, was treated as a component of consideration transferred. See Note 5, “Merger.”
	The exchange of the Private Epirus stock options for stock options to purchase Public Epirus Common Stock was treated as a modification of the awards. The modification of the stock options did not result in any incremental compensation expense as the modification did not increase the fair value of the stock options.
	Stock Options
	A summary of stock option activity during the nine months ended September 30, 2014 is as follows:
								Weighted-
								Average
					Weighted-			Remaining
					Average			Contractual		Aggregate
		Number			Exercise			Term		Intrinsic
		of Options			Price			(in years)		Value
	Outstanding at December 31, 2013	458,871			$	0.96
	Granted	1,143,076			7.95
	Options assumed in Merger	134,454			72.02
	Exercised	(98,405		)	0.91
	Cancelled	(52,098		)	16.85
	Outstanding at September 30, 2014	1,585,898			$	11.5		9.1		$	7,810
	Vested and expected to vest at: September 30, 2014	1,534,073			$	11.65		9		$	7,556
	Exercisable at: September 30, 2014	289,667			$	5.97		7.5		$	1,440
	Weighted average grant-date fair value of options granted during the period	$	6.01
	The aggregate intrinsic value in the table above represents the value (the difference between the Company’s common stock fair value on September 30, 2014 and the exercise price of the options, multiplied by the number of in-the-money options) that would have been received by the option holders had all option holders exercised their options on September 30, 2014. As of September 30, 2014, there was $4,992 of total unrecognized stock-based compensation expense related to stock options granted under the plans. The expense is expected to be recognized over a weighted-average period of 3.48 years.
	During the three and nine months ended September 30, 2014 and 2013, respectively, the range of assumptions used in the Black-Scholes pricing model for new grants and grants issued or accelerated in connection with the Merger were as follows:
		Three Months Ended September 30,				Nine Months Ended September 30,
		2014		2013		2014		2013
	Risk-free interest rate	1.95% - 2.01%		1.81%		1.91% - 2.09%		1.09% - 1.81%
	Expected volatility	65.84% - 65.94%		66.99%		64.07% - 66.07%		66.99%
	Expected term (in years)	6.00		6.00		6.00		6.00
	Expected dividend yield	0.0%		0.0%		0.0%		0.0%
	Restricted Stock
	In April 2014, the Company granted 53,036 shares of restricted common stock to a vendor for consulting services. The restricted common stock is subject to certain performance-based vesting conditions under which 25% of the award vested on April 15, 2014 and the remaining 75% would vest following the successful achievement of certain performance milestones and the passage of time. For the 13,259 shares that vested during April 2014, the Company recorded $98 to general and administrative expense in the condensed consolidated statement of operations and comprehensive loss during the nine months ended September 30, 2014. In addition, the Company was obligated to pay an upfront fee of $200 and is obligated to pay a monthly consulting fee of $25 for a period of 18 months. The upfront fee of $200 was recorded to general and administrative expense in the condensed consolidated statement of operations and comprehensive loss during the nine months ended September 30, 2014.
	In September 2014, an additional 50% of the 53,036 shares of restricted common stock granted in April 2014 vested as a result of certain performance milestones being achieved. Upon such shares’ vesting, the Company recorded $185 to general and administrative expense in the condensed consolidated statement of operations and comprehensive loss. The remaining 25% of the 53,056 shares of restricted common stock are expected to vest in September 2015.
	A summary of the restricted stock activity during the nine months ended September 30, 2014 is as follows:
		Restricted		Weighted-
		Stock		Average Grant
				Date Fair Value
	Nonvested at December 31, 2013	—		$	—
	Granted	58,560		5.08
	Vested	(45,301	)	5.08
	Cancelled	—		—
	Nonvested at September 30, 2014	13,259		$	5.08
	RSUs
	Prior to the Merger, Zalicus had outstanding 52,777 nonvested RSUs, which were issued to certain employees. In connection with the Merger, pursuant to their original agreements, the Company assumed the RSUs. In connection with the Merger, 25,000 of the RSUs vested immediately. Such shares are included in the number of shares of Public Epirus Common Stock owned by Zalicus stockholders used in the calculation of consideration transferred in the Merger. See Note 5, “Merger,” for additional details. Pursuant to their original agreements, the remaining 27,777 RSUs vested upon termination of the employees’ following the Merger. Upon the acceleration of vesting of such RSUs, the Company recognized $277 of postcombination stock-based compensation expense, which represents the portion of the acquisition-date fair value of such RSUs that was not attributable to precombination service. A summary of the RSUs activity during the nine months ended September 30, 2014 is as follows:
		Restricted		Weighted-			Weighted-Average		Aggregate
		Stock Units		Average Grant			Remaining		Intrinsic
				Date Fair Value			Contractual Term		Value
	Nonvested at December 31, 2013	—		$	—
	Granted	27,777		11.8
	Vested	(27,777	)	11.8
	Cancelled	—		—
	Nonvested at September 30, 2014	—		$	—		—		$	—
	The table above does not include the 25,000 Zalicus RSUs that vested immediately in connection with the Merger.

Income_Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2014
Income Taxes	'
Income Taxes	'
	13.Income Taxes
	For the three months ended September 30, 2014, the Company recorded an income tax benefit of $21, which is due primarily to a tax benefit of $46 from the amortization of the Company’s deferred tax benefit related to the transfer of IPR&D to the Company’s subsidiary, Epirus Switzerland GmbH, a Swiss corporation, offset by $25 withholding tax in Switzerland. For the three months ended September 30, 2013, the Company recorded an income tax benefit of $16 related to an adjustment of the deferred tax liability.
	For the nine months ended September 30, 2014, the Company recorded income tax expense of $18 which is due to $76 of income tax expense in Brazil and $100 of withholding tax in Switzerland offset by a tax benefit of $138 from the amortization of the Company’s deferred tax benefit and a $20 tax benefit from the reversal of AMT due for fiscal 2013. For the nine months ended September 30, 2013, the Company recorded an income tax benefit of $16 related to an adjustment of its deferred tax liability.
	The Company has evaluated the positive and negative evidence on the realizability of its deferred tax assets in each jurisdiction and management has determined that it is more likely than not that the Company will not utilize the benefits of its deferred tax assets in each jurisdiction except Brazil for financial reporting purposes. Accordingly, the deferred tax assets have been fully reserved as of September 30, 2014 and December 31, 2013.

Commitments

Commitments	9 Months Ended
	Sep. 30, 2014
Commitments	'
Commitments	'
	14.Commitments
	On May 15, 2014, the Company amended its March 2013 operating lease for office space in Boston, Massachusetts (the “First Amendment”). The First Amendment provides the Company additional square footage on a new floor of the office. The Company has committed to lease this space for a period of seven years. The First Amendment contains rent escalation, rent holiday, and leasehold improvement incentives. Rent escalation and rent holiday are being accounted for as rent expense under the straight-line method. Deferred rent is included in other non-current liabilities in the condensed consolidated balance sheet as of September 30, 2014. The Company will record rent expense of approximately $38 per month on a straight-line basis over the effective lease term.
	In connection with the First Amendment, the Company received approximately $477 in leasehold improvement incentives from the landlord. These leasehold improvement incentives are being accounted for as a reduction in rent expense ratably over the lease term. The balance from these leasehold improvement incentives is included in other current liabilities and other non-current liabilities in the condensed consolidated balance sheet. The leasehold improvements are included in property and equipment and are being amortized using the straight-line method over the term of the lease, which is the shorter of the estimated useful lives of the assets and the term of the lease.
	Future minimum lease payments under the First Amendment are as follows:
		September 30, 2014
	Remainder of 2014	$	111
	2015	448
	2016	456
	2017	464
	2018	472
	2019 and thereafter	1,297
	Total	$	3,248

Net_Loss_per_share

Net Loss per share	9 Months Ended
	Sep. 30, 2014
Net Loss per share	'
Net Loss per share	'
	15.Net Loss Per Share
	The Company computes basic and diluted loss per share using a methodology that gives effect to the impact of outstanding participating securities (the “two-class method”). As the nine month periods ended September 30, 2014 and 2013 resulted in net losses, there is no income allocation required under the two-class method or dilution attributed to weighted-average shares outstanding in the calculation of diluted loss per share.
	The following potentially dilutive securities outstanding, prior to the use of the treasury stock method, have been excluded from the computation of diluted weighted-average shares outstanding for the three and nine month periods ended September 30, 2014 and 2013, as they would be anti-dilutive.
		As of September 30,
		2014	2013
	Convertible preferred stock	—	27,248,746
	Convertible notes	—	7,770,905
	Options to purchase common stock	1,585,898	458,871
	Warrants to purchase preferred stock	—	4,267,727
	Warrants to purchase common stock	86,190	—
	Nonvested restricted stock	13,259	—

Legal_Proceedings

Legal Proceedings	9 Months Ended
	Sep. 30, 2014
Legal Proceedings	'
Legal Proceedings	'
	16.Legal Proceedings
	From time to time, the Company is involved in legal proceedings and claims of various types and accounts for these legal proceedings in accordance with ASC Topic 450, “Contingencies.” The Company records a liability in its consolidated financial statements for these matters when a loss is considered probable and the amount of loss can be reasonably estimated. The Company reviews these estimates each accounting period as additional information is known and adjusts the loss provision when appropriate. If the loss is not probable or cannot be reasonably estimated, a liability is not recorded in its consolidated financial statements.
	Between April 28, 2014 and May 2, 2014, three putative class action lawsuits were filed by purported stockholders of Zalicus in the Business Litigation Session of the Massachusetts Superior Court, Suffolk County, against Zalicus, EB Sub, Inc. the members of Zalicus’ board of directors and Private Epirus. Plaintiff has since voluntarily dismissed one of these actions, Civil A. No. 14-1380. The remaining two actions, Civ. A. No. 14-1381 and Civ. A. No. 14-1455, have been consolidated into a single action, In re Zalicus Shareholder Litigation, Lead Civ. A. No. 14-1381 (the “Massachusetts Action”). The Massachusetts Action alleges that the Zalicus board of directors breached its fiduciary duties, and that Private Epirus and EB Sub, Inc. aided and abetted the purported breaches, in connection with the proposed Merger. The Massachusetts Action seeks relief including, among other things, a declaration that the Merger Agreement was entered into in breach of fiduciary duties and is unlawful and unenforceable, an order enjoining defendants from proceeding with the Merger, an order enjoining defendants from consummating the Merger unless and until additional procedures are implemented and all material information in connection with the proposed Merger is disclosed, rescission of the Merger or any terms thereof to the extent implemented (or an award of rescissory damages), compensatory damages and interest, and an award of all costs of the Massachusetts Actions, including reasonable attorneys’ fees and experts’ fees.
	Between May 1, and May 16, 2014, three putative class action lawsuits were filed by purported stockholders of Zalicus in the Court of Chancery of the State of Delaware against Zalicus, Zalicus’ directors, Private Epirus and/or EB Sub, Inc., Stein v. Zalicus Inc., et al. , No. 9602;  Do v. Zalicus, Inc., et al. , No. 9636; and Mendlowitz, et al. v. Zalicus Inc., et al. , No. 9664 (the “Delaware Actions”). On May 23, 2014, plaintiff Harvey Stein filed a verified amended complaint, and on May 27, 2014, plaintiff Tuan Do filed a verified amended complaint. The Delaware Actions allege that the Zalicus board of directors breached their fiduciary duties, and Private Epirus and/or EB Sub, Inc. aided and abetted the purported breaches, in connection with the proposed Merger. The Delaware Actions seek relief including, among other things, to preliminarily and permanently enjoin the proposed Merger, to enjoin consummation of the proposed Merger and rescind the Merger if consummated (or to award rescissionary damages), an award of compensatory damages, and an award of all costs of the Delaware Actions, including reasonable attorneys’ fees and experts’ fees.
	On June 6, 2014, plaintiffs’ counsel in the Delaware Actions filed a motion seeking to schedule a preliminary injunction hearing in advance of the stockholder vote on the proposed Merger, and seeking expedited discovery in advance of that hearing. Zalicus, Private Epirus, and the individual defendants opposed the motion. After a hearing, on June 13, 2014, the Delaware Court of Chancery denied plaintiffs’ motion.
	On October 27, 2014, plaintiffs’ counsel in the Massachusetts actions served the Company with a motion for voluntary dismissal and an award of attorney’s fees. The motion alleges, as set forth in the consolidated amended complaint filed in the Massachusetts actions on May 21, 2014, that the Form S-4 Registration Statement filed with the SEC on May 8, 2014 contained numerous material misstatements and/or omissions that prevented the Company’s shareholders from being able to evaluate the reasonableness of the Merger. The motion further alleges that in the Amended Registration Statement filed on June 4, 2014, the Company supplemented the disclosures and addressed the allegedly material misstatements and omissions contained in the initial Registration Statement, and that the Company did so in response to the claims made in the Massachusetts Actions.  Plaintiffs’ counsel seeks an award of $350 in fees and expenses. The Company disputes the contentions in the motion and will vigorously defend against the claim.
	The defendants deny the allegations in the Massachusetts Action and Delaware Actions, believe the actions are meritless, and intend to vigorously defend the actions. At each reporting period, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable. In light of the early stages of the Massachusetts Action and Delaware Actions, an estimate of the amount or range of reasonably possible loss in connection with these matters cannot be made.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2014
Summary of Significant Accounting Policies (Policies)	'
Revenue Recognition	'
	Revenue Recognition
	Multiple-Element Arrangements
	Under the authoritative guidance for revenue recognition related to multiple-element revenue arrangements, each deliverable within a multiple-element revenue arrangement is accounted for as a separate unit of accounting if both of the following criteria are met: (1) the delivered item or items have value to the customer on a standalone basis and (2) for an arrangement that includes a general right of return relative to the delivered item(s), delivery or performance of the undelivered item(s) is considered probable and substantially in the Company’s control. The Company considers a deliverable to have standalone value if the Company sells this item separately or if the item is sold by another vendor or could be resold by the customer. Deliverables not meeting the criteria for being a separate unit of accounting are accounted for on a combined basis.
	In the event the Company enters into a contract in which the deliverables are required to be separated, the Company will allocate arrangement consideration to each deliverable in an arrangement based on its relative selling price. The Company determines selling price using vendor-specific objective evidence (“VSOE”), if it exists; otherwise, the Company uses third-party evidence (“TPE”). If neither VSOE nor TPE of selling price exists for a deliverable, the Company uses estimated selling price (“ESP”) to allocate the arrangement consideration. The Company applies appropriate revenue recognition guidance to each unit of accounting.
	Milestones
	Contingent consideration from research and development activities that is earned upon the achievement of a substantive milestone is recognized in its entirety in the period in which the milestone is achieved. At the inception of each arrangement that includes milestone payments, the Company evaluates whether each milestone is substantive. This evaluation includes an assessment of whether: (a) the consideration is commensurate with either (1) the entity’s performance to achieve the milestone, or (2) the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting from the entity’s performance to achieve the milestone, (b) the consideration relates solely to past performance and (c) the consideration is reasonable relative to all of the deliverables and payment terms within the arrangement. The Company evaluates factors such as the scientific, clinical, regulatory, commercial and other risks that must be overcome to achieve the respective milestone, the level of effort and investment required and whether the milestone consideration is reasonable relative to all deliverables and payment terms in the arrangement in making this assessment.
In-process Research & Development	'
	In-process Research & Development
	In-process research & development (“IPR&D”) represents the fair value assigned to research and development assets that were not fully developed at the date of acquisition. IPR&D acquired in a business combination or recognized from the application of push-down accounting is capitalized on the Company’s consolidated balance sheet at its acquisition-date fair value. Until the project is completed, the assets are accounted for as indefinite-lived intangible assets and subject to impairment testing. Upon completion of a project, the carrying value of the related IPR&D is reclassified to intangible assets and is amortized over the estimated useful life of the asset.
	When performing the impairment assessment, the Company first assesses qualitative factors to determine whether it is necessary to recalculate the fair value of its acquired IPR&D. If the Company believes, as a result of the qualitative assessment, that it is more likely than not that the fair value of acquired IPR&D is less than its carrying amount, it calculates the asset’s fair value. If the carrying value of the Company’s acquired IPR&D exceeds its fair value, then the intangible asset is written down to its fair value. For the nine months ended September 30, 2014, the Company determined that there was no impairment of its IPR&D.
Intangible Assets	'
	Intangible Assets
	The Company amortizes its intangible assets using the straight-line method over its estimated economic life, which is approximately 16.5 years. The Company evaluates the potential impairment of its other intangible assets if events or changes in circumstances indicate that the carrying amount of the assets may not be fully recoverable or that the useful life of the assets is no longer appropriate. The impairment test is based on a comparison of the undiscounted cash flows expected to be generated from the use of the asset group and its eventual disposition to the carrying value of the asset group. If impairment is indicated, the assets are written down by the amount by which the carrying value of the assets exceeds the related fair value of the assets. Any write-downs are treated as permanent reductions in the carrying value of the assets.
Recent Accounting Pronouncements	'
	Recent Accounting Pronouncements
	Revenue Recognition
	In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers, which amends the guidance for accounting for revenue from contracts with customers. This ASU supersedes the revenue recognition requirements in Accounting Standards Codification Topic 605, Revenue Recognition, and creates a new Topic 606, Revenue from Contracts with Customers. This guidance is effective for fiscal years beginning after December 15, 2016, with early adoption not permitted. Two adoption methods are permitted: retrospectively to all prior reporting periods presented, with certain practical expedients permitted; or retrospectively with the cumulative effect of initially adopting the ASU recognized at the date of initial application. The Company has not yet determined which adoption method it will utilize or the effect that the adoption of this guidance will have on its consolidated financial statements.
	Discontinued Operations and Disposals
	In April 2014, the FASB issued ASU No. 2014-8, Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity (“ASU 2014-8”). ASU 2014-8 changes the criteria for determining which disposals can be presented as discontinued operations and modifies related disclosure requirements. Under the new guidance, a discontinued operation is defined as a disposal of a component or group of components that is disposed of or is classified as held for sale and represents a strategic shift that has a major effect on an entity’s operations and financial results. This accounting guidance applies prospectively to new disposals and new classifications of disposal groups as held for sale. The guidance is effective for fiscal years beginning after December 15, 2014.
	Development Stage Entity
	In June 2014, the FASB issued ASU No. 2014-10, Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation (“ASU 2014-10”). ASU 2014-10 removes all incremental financial reporting requirements from GAAP for development stage entities, including the removal of Topic 915 from the FASB Accounting Standards Codification (“ASC”). In addition, the update adds an example disclosure in Risks and Uncertainties, ASC Topic 275, to illustrate one way that an entity that has not begun planned principal operations could provide information about the risks and uncertainties related to the company’s current activities and removes an exception provided to development stage entities in Consolidations, ASC Topic 810, for determining whether an entity is a variable interest entity—which may change the consolidation analysis, consolidation decision, and disclosure requirements for a company that has an interest in a company in the development stage. ASU 2014-10 is effective for fiscal years beginning after December 15, 2014 with the revised consolidation standards effective for fiscal years beginning after December 15, 2016. Early adoption is permitted. The Company early adopted the guidance and eliminated the presentation and disclosure requirements of ASC Topic 915 during the three months ending June 30, 2014.

Merger_Tables

Merger (Tables)	9 Months Ended
	Sep. 30, 2014
Merger	'
Schedule of acquisition-date fair value of consideration transferred	'
	Number of shares of Public Epirus Common Stock owned by Zalicus stockholders (1)		2,635,871
	Multiplied by the price per share of Public Epirus Common Stock (2)		$	11.80
	Fair value of shares of Public Epirus Common Stock owned by Zalicus stockholders		$	31,104
	Acquisition-date fair value of assumed Zalicus equity awards attributable to precombination services (3)		$	220
	Total consideration transferred		$	31,324
		-1		The stock transferred in the table above is comprised of 2,610,871 common shares outstanding at the time of the Merger plus 25,000 restricted stock units (RSUs) that vested immediately upon the closing of the Merger. The fair value of shares of Public Epirus Common Stock owned by Zalicus shareholders of $31,104 includes approximately $1 related to fractional shares resulting from the Reverse Stock Split.
		-2		The shares outstanding are multiplied by the closing trading price of Public Epirus Common Stock as of the Merger date.
		-3		Consideration transferred includes approximately $220 of Zalicus equity awards assumed and deemed attributable to precombination services to Zalicus. This amount excludes approximately $355 of acquisition-date fair value attributable to postcombination service, which was recorded to reflect the acceleration of nonvested equity awards of Zalicus upon the termination of certain Zalicus employees after the Merger. The Company recognized the $355 as stock-based compensation expense in the postcombination period ended September 30, 2014 (Note 12). The fair value of the equity awards at July 15, 2014 was determined using a Black-Scholes option-pricing model with the following ranges of assumptions: exercise price of $14.70 per share to $591.00 per share; underlying stock value of $11.80 per share; expected volatility of 66.02%; expected term of 0.1 years to 6.0 years; and risk-free interest rate of 1.91%.
Summary of estimated fair values of the assets acquired and liabilities assumed at date of acquisition	'
			July 15, 2014
	Cash and cash equivalents		$	13,756
	In-process research and development		5,500
	Goodwill		14,864
	Restricted cash		1,850
	Other assets		253
	Total assets acquired		36,223
	Accounts payable		(1,584		)
	Accrued expenses and other current liabilities		(757		)
	Other liabilities		(391		)
	Deferred tax liabilities		(2,166		)
	Total liabilities assumed		(4,899		)
	Total net assets acquired		$	31,324
Supplemental unaudited pro forma information as if acquisition had occurred on January 1, 2013	'
			Nine Months Ended
			September 30,
			2014			2013
	Total revenues, net		$	2,735		$	14,731
	Net loss		(22,025		)	(61,727		)

Goodwill_IPRD_and_Intangible_A1

Goodwill, IPR&D and Intangible Assets, Net (Tables)	9 Months Ended
	Sep. 30, 2014
Goodwill, IPR&D and Intangible Assets, Net	'
Schedule of Changes in Goodwill	'
	Balance at December 31, 2013	$	1,499
	Goodwill related to Merger	14,864
	Balance at September 30, 2014	$	16,363
Schedule of Intangible Assets	'
		September 30, 2014			December 31, 2013
	Intangible assets	$	3,687		$	—
		3,687			—
	Less: accumulated amortization—intangible assets	(26		)	—
	Intangible assets, net	$	3,661		$	—
Schedule of estimated aggregate amortization of intangible assets	'
		September 30, 2014
	Remainder of 2014	$	56
	2015	225
	2016	225
	2017	225
	2018	225
	2019 and thereafter	2,705
	Total	$	3,661

Accrued_Expenses_and_Other_Cur1

Accrued Expenses and Other Current Liabilities (Tables)	9 Months Ended
	Sep. 30, 2014
Accrued Expenses and Other Current Liabilities	'
Components of Accrued expenses	'
		September 30, 2014		December 31, 2013
	Accrued professional fees	$	1,034	$	544
	Accrued compensation	1,004		725
	Accrued manufacturing expense	603		380
	Accrued clinical expense	455		286
	Accrued royalty settlement	1,400		—
	Accrued interest expense	—		502
	Other	130		55
	Total accrued expenses	$	4,626	$	2,492

Warrants_Tables

Warrants (Tables)	9 Months Ended
	Sep. 30, 2014
Common Stock [Member]	'
Schedule of warrants to purchase stock outstanding	'
		As of September 30, 2014
		Number of
		Shares	Exercise
		Underlying	Price
		Warrant	Per Share
	Common Stock	20,953	$	7.55
	Common Stock	1,043	$	0.08
	Common Stock	64,194	$	7.01
Preferred Stock [Member]	'
Schedule of warrants to purchase stock outstanding	'
		As of December 31, 2013
		Number of
		Shares	Exercise		Fair Value at
		Underlying	Price		December 31,
		Warrant	Per Share		2013
	Series A Preferred	462,399	$	1.00	$	311
	Series A Preferred	4,805,327	$	0.01	$	5,532

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2014
Fair Value Measurements	'
Schedule of financial assets and financial liabilities measured at fair value on a recurring basis	'
		As of September 30, 2014
		Level 1			Level 2		Level 3		Total
	Assets
	Cash and cash equivalents	$	23,681		$	—	$	—	$	23,681
		$	23,681		$	—	$	—	$	23,681
		As of December 31, 2013
		Level 1			Level 2		Level 3		Total
	Assets
	Cash and cash equivalents	$	1,798		$	—			$	1,798
		$	1,798		$	—	$	—	$	1,798
	Liabilities
	Warrant liability	$	—		$	—	$	5,843	$	5,843
		$	—		$	—	$	5,843	$	5,843
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]	'
Quantitative information about the fair value measurements used in the valuations of the warrant liability and embedded compounded derivative:	'
		Valuation Assumptions as of
		June 30, 2014		April 15, 2014		March 31, 2014	March 10, 2014
	Hybrid approach
	Discount rate	*		21% to 30%		25% to 30%	25% to 30%
	Probability weighted value for common stock	20% to 80%		30% to 70%		45% to 55%	45% to 55%
	Discount for lack of marketability	5% to 30%		11% to 34%		10% to 28%	10% to 28%
	With and Without approach
	Probability of occurrence of certain events	**		0% to 100%		5% to 50%	5% to 50%
	Market yield	**		25%		25%	25%
	Recovery rate	**		31% to 47%		31% to 47%	31% to 47%
	* Discount rate not used as DCF was not calculated.
	** No compound derivative to fair value at June 30, 2014.
Warrant [Member]	'
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]	'
Schedule of changes in the fair value of liabilities determined using Level 3 inputs	'
		September 30, 2014
	Balance at December 31, 2013	$	5,843
	Warrant issuance	1,171
	Change in fair value	222
	Warrant exercises	(7,069		)
	Reclassification to equity	(167		)
	Balance at September 30, 2014	$	—
Embedded Derivative Financial Instruments [Member]	'
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]	'
Schedule of changes in the fair value of liabilities determined using Level 3 inputs	'
		September 30, 2014
	Balance at December 31, 2013	$	—
	Embedded compound derivative	23
	Change in fair value	—
	Derecognition of embedded compound derivative	(23		)
	Balance at September 30, 2014	$	—

StockBased_Compensation_Tables

Stock-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2014
Stock-Based Compensation	'
Summary of stock option activity	'
								Weighted-
								Average
					Weighted-			Remaining
					Average			Contractual		Aggregate
		Number			Exercise			Term		Intrinsic
		of Options			Price			(in years)		Value
	Outstanding at December 31, 2013	458,871			$	0.96
	Granted	1,143,076			7.95
	Options assumed in Merger	134,454			72.02
	Exercised	(98,405		)	0.91
	Cancelled	(52,098		)	16.85
	Outstanding at September 30, 2014	1,585,898			$	11.5		9.1		$	7,810
	Vested and expected to vest at: September 30, 2014	1,534,073			$	11.65		9		$	7,556
	Exercisable at: September 30, 2014	289,667			$	5.97		7.5		$	1,440
	Weighted average grant-date fair value of options granted during the period	$	6.01
Summary of weighted-average assumptions used in the Black-Scholes pricing model	'
		Three Months Ended September 30,				Nine Months Ended September 30,
		2014		2013		2014		2013
	Risk-free interest rate	1.95% - 2.01%		1.81%		1.91% - 2.09%		1.09% - 1.81%
	Expected volatility	65.84% - 65.94%		66.99%		64.07% - 66.07%		66.99%
	Expected term (in years)	6.00		6.00		6.00		6.00
	Expected dividend yield	0.0%		0.0%		0.0%		0.0%
Summary of restricted stock activity	'
		Restricted		Weighted-
		Stock		Average Grant
				Date Fair Value
	Nonvested at December 31, 2013	—		$	—
	Granted	58,560		5.08
	Vested	(45,301	)	5.08
	Cancelled	—		—
	Nonvested at September 30, 2014	13,259		$	5.08
Summary of RSUs activity	'
		Restricted		Weighted-			Weighted-Average		Aggregate
		Stock Units		Average Grant			Remaining		Intrinsic
				Date Fair Value			Contractual Term		Value
	Nonvested at December 31, 2013	—		$	—
	Granted	27,777		11.8
	Vested	(27,777	)	11.8
	Cancelled	—		—
	Nonvested at September 30, 2014	—		$	—		—		$	—

Commitments_Tables

Commitments (Tables)	9 Months Ended
	Sep. 30, 2014
Commitments	'
Schedule of Future Minimum Lease Payments under Operating Leases	'
		September 30, 2014
	Remainder of 2014	$	111
	2015	448
	2016	456
	2017	464
	2018	472
	2019 and thereafter	1,297
	Total	$	3,248

Net_Loss_per_share_Tables

Net Loss per share (Tables)	9 Months Ended
	Sep. 30, 2014
Net Loss per share	'
Summary of potentially dilutive securities outstanding excluded from the computation of diluted weighted-average shares outstanding	'
		As of September 30,
		2014	2013
	Convertible preferred stock	—	27,248,746
	Convertible notes	—	7,770,905
	Options to purchase common stock	1,585,898	458,871
	Warrants to purchase preferred stock	—	4,267,727
	Warrants to purchase common stock	86,190	—
	Nonvested restricted stock	13,259	—

Organization_Details

Organization (Details) (USD $)	12 Months Ended
In Billions, unless otherwise specified	Dec. 31, 2013
Johnson & Johnson, Merck Schering and Mitsubishi Tanabe [Member]	'
Business Acquisition	'
Global sales	$8.40
Abbvie Member	'
Business Acquisition	'
Global sales	$26.20

Basis_of_Presentation_Details

Basis of Presentation (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013	Jul. 16, 2014	Jul. 16, 2014
			Common Class A [Member]	Common Class A [Member]
			Zalicus [Member]	Zalicus [Member]
Reverse stock split	'	'	'	'
Reverse stock split conversion ratio	'	'	0.1	'
Common stock (par value)	$0.00	$0.00	'	$0.00

Significant_Accounting_Policie

Significant Accounting Policies (Details)	9 Months Ended
	Sep. 30, 2014
Summary of Significant Accounting Policies (Policies)	'
Intangible asset, useful life	'16 years 6 months

Business_Agreements_Details

Business Agreements (Details) (USD $)

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Sep. 30, 2014

Oct. 31, 2014

Sep. 30, 2014

Sep. 30, 2014

Apr. 30, 2014

Jan. 31, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2014

In Thousands, unless otherwise specified

Moksha8 Pharmaceuticals Inc [Member]

Moksha8 Pharmaceuticals Inc [Member]

Moksha8 Pharmaceuticals Inc [Member]

Royalty Bearing And Non Transferable License Agreement [Member]

Royalty Bearing And Non Transferable License Agreement [Member]

Royalty Bearing And Non Transferable License Agreement [Member]

Royalty Bearing And Non Transferable License Agreement [Member]

Royalty Bearing And Non Transferable License Agreement [Member]

Orygen Heads Of Agreement [Member]

Orygen Heads Of Agreement [Member]

Supply Agreement [Member]

Exclusive License And Collaboration Agreement [Member]

BOW015 [Member]

BOW015 [Member]

BOW015 [Member]

Ranbaxy Laboratories Limited [Member]

Ranbaxy Laboratories Limited [Member]

Ranbaxy Laboratories Limited [Member]

Ranbaxy Laboratories Limited [Member]

BOW015 [Member]

Orygen Biotechnology [Member]

Ranbaxy Laboratories Limited [Member]

Livzon Mabpharm Inc [Member]

item

item

BOW015 [Member]

BOW015 [Member]

BOW015 [Member]

BOW015 [Member]

BOW015 [Member]

BOW015 [Member]

item

Business Agreements

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Upfront payment received

'

'

'

'

'

'

'

'

$500

'

'

$250

'

'

Maximum payments to be received for achievement of certain development and regulatory approval milestones

'

'

'

'

'

'

'

'

1,000

'

'

'

'

'

Maximum payments to be received for achievement of certain sales milestones

'

'

'

'

'

'

'

'

10,000

'

'

'

'

'

Percentage of upfront payments and payments to be received for achievement of certain development and regulatory approval milestones refundable to Ranbaxy

'

'

'

'

'

'

'

'

50.00%

'

'

'

'

'

Number of units of accounting for recognition of revenue of deliverables

'

'

'

'

'

1

'

'

'

'

'

'

'

'

Billings to Ranbaxy

'

'

'

'

'

'

125

250

125

1,000

'

'

'

'

Proceeds received from Ranbaxy

'

'

'

'

'

'

'

'

'

1,000

'

'

'

'

Term of agreement

'

'

'

'

'

'

'

'

'

'

'

'

'10 years

'20 years

Automatic renewal period

'

'

'

'

'

'

'

'

'

'

'

'

'2 years

'

Revenue recognized from rights under agreement

'

'

'

'

'

'

'

'

'

'

250

'

'

'

Maximum additional compounds subject to exclusive, royalty-bearing licenses

'

'

'

'

'

'

'

'

'

'

'

'

'

4

Payments to be received for achievement of specified regulatory milestones

'

'

'

'

'

'

'

'

'

'

'

'

'

2,500

Payment to terminate payment obligations under agreement

'

'

'

1,500

1,400

'

'

'

'

'

'

'

'

'

Payments made under the agreement

'

'

'

0

1,400

'

'

'

'

'

'

'

'

'

Number of payment installments to terminate obligations under agreement

'

'

'

2

'

'

'

'

'

'

'

'

'

'

Accrued royalty settlement

1,400

'

'

1,400

'

'

'

'

'

'

'

'

'

'

Accrued royalty obligations

'

'

'

150

'

'

'

'

'

'

'

'

'

'

Intangible asset

$5,500

$2,437

'

$1,250

$1,250

'

'

'

'

'

'

'

'

'

Ownership percentage

'

'

17.00%

'

'

'

'

'

'

'

'

'

'

'

Merger_Details

Merger (Details) (USD $)

3 Months Ended

9 Months Ended

0 Months Ended

3 Months Ended

9 Months Ended

9 Months Ended

0 Months Ended

0 Months Ended

0 Months Ended

0 Months Ended

In Thousands, except Share data, unless otherwise specified

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Dec. 31, 2013

Jul. 31, 2014

Jul. 15, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2013

Jul. 15, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2013

Jul. 15, 2014

Jul. 15, 2014

Jul. 15, 2014

Jul. 15, 2014

Jul. 15, 2014

Jul. 15, 2014

Jul. 15, 2014

Jul. 15, 2014

Jul. 15, 2014

In Process Research and Development [Member]

Zalicus [Member]

Zalicus [Member]

Zalicus [Member]

Zalicus [Member]

Zalicus [Member]

Zalicus [Member]

Zalicus [Member]

Zalicus [Member]

Zalicus [Member]

Zalicus [Member]

Zalicus [Member]

Zalicus [Member]

Zalicus [Member]

Zalicus [Member]

Zalicus [Member]

Zalicus [Member]

Zalicus [Member]

Zalicus [Member]

Zalicus [Member]

Transaction Costs [Member]

StockBasedCompensationExpense [Member]

SeveranceAgreementExpense [Member]

OtherExpenseRelatedToChangeInFairValueOfLiabilityClassifiedWarrants [Member]

OtherExpenseRelatedToChangeInFairValueOfLiabilityClassifiedWarrants [Member]

In Process Research and Development [Member]

In Process Research and Development [Member]

Minimum [Member]

Minimum [Member]

Maximum [Member]

Maximum [Member]

Common Stock [Member]

RestrictedStockUnitsVestedUponClosingOfBusinessCombinationMember

Common Class A [Member]

Merger

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of shares of acquiree received for each share of acquirer exchanged

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0.13259

Aggregate number of acquiree shares received for acquirer shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

10,288,180

Number of acquiree shares received for future issuance upon exercies of stock options

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,152,042

Number of acquiree shares received for future issuance upon exercies of warrants

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

21,996

Acquisition-date fair value of the consideration transferred

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of Public Epirus Common Stock owned by Zalicus stockholders (1)

'

'

'

'

'

'

2,635,871

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,610,871

25,000

'

Multiplied by the price per share of Public Epirus Common Stock (2) (in dollars per share)

'

'

'

'

'

'

'

'

'

'

$11.80

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair value of shares of Public Epirus Common Stock owned by Zalicus stockholders

'

'

'

'

'

'

$31,104

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Acquisition-date fair value of assumed Zalicus equity awards attributable to precombination services (3)

'

'

'

'

'

'

220

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Total consideration transferred

'

'

'

'

'

'

31,324

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Amount of fractional shares resulting from Reverse Stock Split included as consideration

'

'

'

'

'

'

1

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock-based compensation expense

943

35

1,314

93

'

'

'

355

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise price (in dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$14.70

'

$591

'

'

'

Share price (in dollars per share)

'

'

'

'

'

'

'

'

'

'

$11.80

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Volatility rate

'

'

'

'

'

'

66.02%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Expected term

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'1 month 6 days

'

'6 years

'

'

'

'

Risk-free interest rate

'

'

'

'

'

'

1.91%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Estimated fair values of the assets acquired and liabilities assumed at the date of acquisition:

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cash and cash equivalents

'

'

'

'

'

'

'

'

'

'

13,756

'

'

'

'

'

'

'

'

'

'

'

'

'

'

In-process research and development

'

'

'

'

'

5,500

'

'

'

'

'

'

'

'

'

'

'

5,500

'

'

'

'

'

'

'

Goodwill

16,363

'

16,363

'

1,499

'

'

'

'

'

14,864

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Restricted cash and other assets

'

'

'

'

'

'

'

'

'

'

1,850

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Other assets

'

'

'

'

'

'

'

'

'

'

253

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Total assets acquired

'

'

'

'

'

'

'

'

'

'

36,223

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Accounts payable

'

'

'

'

'

'

'

'

'

'

-1,584

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Accrued expenses and other current liabilities

'

'

'

'

'

'

'

'

'

'

-757

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Other liabilities

'

'

'

'

'

'

'

'

'

'

-391

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Deferred tax liabilities

'

'

'

'

'

'

'

'

'

'

-2,166

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Total liabilities assumed

'

'

'

'

'

'

'

'

'

'

-4,899

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Total net assets acquired

'

'

'

'

'

'

'

'

'

'

31,324

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Discount rate (as a percent)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

13.10%

'

'

'

'

'

'

'

'

Sublease liability

'

'

'

'

'

'

376

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Effective tax rate

'

'

'

'

'

'

39.39%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Operating loss from date of acquisition included in financial statements

'

'

'

'

'

'

'

25

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Business Combination, Acquisition Related Costs

'

'

'

'

'

'

5,665

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Supplemental unaudited pro forma information as if acquisition had occurred on January 1, 2013:

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Total revenues, net

'

'

'

'

'

'

'

'

2,735

14,731

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net loss

'

'

'

'

'

'

'

'

-22,025

-61,727

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net loss

($13,935)

($4,278)

($31,445)

($13,022)

'

'

'

'

'

'

'

$8,559

$355

$1,980

$222

$805

'

'

'

'

'

'

'

'

'

Goodwill_IPRD_and_Intangible_A2

Goodwill, IPR&D and Intangible Assets, Net (Details) (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014
Change in Goodwill	'
Goodwill, Beginning Balance	$1,499
Goodwill related to Merger	14,864
Goodwill, Ending Balance	16,363
Accumulated goodwill impairment losses	$0

Goodwill_IPRD_and_Intangible_A3

Goodwill, IPR&D and Intangible Assets, Net (Details 2) (USD $)	9 Months Ended		1 Months Ended	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Dec. 31, 2013	Jul. 31, 2014	Sep. 30, 2014	Sep. 30, 2013	Oct. 31, 2014	Sep. 30, 2014
			In Process Research and Development [Member]	In Process Research and Development [Member]	In Process Research and Development [Member]	BOW015 [Member]	BOW015 [Member]
						Moksha8 Pharmaceuticals Inc [Member]	Moksha8 Pharmaceuticals Inc [Member]
Intangible Assets	'	'	'	'	'	'	'
In-process research and development	'	'	$5,500	'	'	'	'
Reclassification from indefinite lived asset to finite lived asset	'	'	2,437	'	'	'	'
Intangible asset, useful life	'16 years 6 months	'	'16 years 6 months	'	'	'	'
Payment to terminate payment obligations under agreement	'	'	'	'	'	1,400	1,500
Intangible asset	5,500	2,437	'	'	'	1,250	1,250
Intangible assets, net of accumulated amortization	'	'	'	'	'	'	'
Intangible assets, gross	3,687	'	'	'	'	'	'
Less: accumulated amortization--intangible assets	-26	'	'	'	'	'	'
Intangible assets, net	3,661	'	'	'	'	'	'
Amortization expense	'	'	'	$26	$0	'	'

Goodwill_IPRD_and_Intangible_A4

Goodwill, IPR&D and Intangible Assets, Net (Details 3) (USD $)	Sep. 30, 2014
In Thousands, unless otherwise specified
Estimated future amortization expense related to finite-lived purchased intangible assets	'
Remainder of 2014	$56
2015	225
2016	225
2017	225
2018	225
2019 and thereafter	2,705
Total	$3,661

Accrued_Expenses_and_Other_Cur2

Accrued Expenses and Other Current Liabilities (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Accrued Expenses and Other Current Liabilities	'	'
Accrued professional fees	$1,034	$544
Accrued compensation	1,004	725
Accrued manufacturing expense	603	380
Accrued clinical expense	455	286
Accrued royalty settlement	1,400	'
Accrued interest expense	'	502
Other	130	55
Total accrued expenses	$4,626	$2,492

Convertible_Debt_Details

Convertible Debt (Details) (USD $)

9 Months Ended

0 Months Ended

1 Months Ended

0 Months Ended

1 Months Ended

9 Months Ended

0 Months Ended

0 Months Ended

1 Months Ended

0 Months Ended

Sep. 30, 2014

Dec. 31, 2013

Apr. 15, 2014

Apr. 30, 2014

Apr. 15, 2014

Mar. 10, 2014

Mar. 10, 2014

Apr. 15, 2014

Mar. 10, 2014

Apr. 30, 2014

Sep. 30, 2014

Mar. 31, 2014

Mar. 10, 2014

Apr. 15, 2014

Mar. 10, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Series B Convertible Preferred Stock [Member]

Series B Convertible Preferred Stock [Member]

Series A Preferred Stock Or Qualified Financing Securities Warrants Exercise Price Dollars 0.01 [Member]

Convertible Debt Issued 2013 [Member]

Convertible Debt Issued 2013 [Member]

Convertible Debt Issued 2014 [Member]

Convertible Debt Issued 2014 [Member]

Convertible Debt Issued 2014 [Member]

Convertible Debt Issued 2014 [Member]

Convertible Debt Issued 2014 [Member]

Convertible Debt Issued 2014 [Member]

Convertible Debt Issued 2014 [Member]

Convertible Debt Issued 2014 [Member]

Hercules Notes Member

Hercules Notes Member

Hercules Term Loan One Member

Hercules Term Loan One Member

Hercules Term Loan Two [Member]

Series B Convertible Preferred Stock [Member]

Series A Convertible Preferred Stock [Member]

item

Series B Convertible Preferred Stock [Member]

Series A Preferred Stock Or Qualified Financing Securities Warrants Exercise Price Dollars 0.01 [Member]

item

Convertible debt

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Outstanding principal amount converted

'

'

'

'

'

$12,500,000

'

$5,000,000

'

$5,000,000

'

'

'

'

'

'

'

'

'

'

Outstanding interest amount converted

'

'

'

'

'

684,000

'

13,000

'

13,000

'

'

'

'

'

'

'

'

'

'

Number of shares issued upon conversion of debt

'

'

3,947,363

3,947,363

'

'

13,184,383

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds received from debt issuance

'

'

'

'

'

'

'

'

5,000,000

'

'

'

'

'

'

'

'

'

'

'

Interest rate (as a percent)

'

'

'

'

'

'

'

'

'

'

'

'

8.00%

'

'

'

'

'

'

'

Warrant coverage (as a percent)

'

'

'

'

'

'

'

'

20.00%

'

'

'

'

'

'

'

'

'

'

'

Minimum gross proceeds from issuance and sale of preferred stock shares to no current holders triggering conversion of debt

'

'

'

'

'

'

'

'

20,000,000

'

'

'

'

'

'

'

'

'

'

'

Minimum number of holders not currently holding capital stock that would need to be issued or sold preferred stock to trigger conversion of debt

'

'

'

'

'

'

'

'

1

'

'

'

'

'

'

'

'

'

'

'

Conversion price in event of corporate merger (in dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

$1

'

'

'

'

'

'

'

Payment multiple of outstanding principal balance in event of acquisition or asset transfer

'

'

'

'

'

'

'

'

3

'

'

'

'

'

'

'

'

'

'

'

Conversion price in event of non-qualified financing (in dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

$1

'

'

'

'

'

'

'

Number of shares issuable upon exercise of warrants

'

'

'

'

787,402

'

'

'

'

'

'

'

'

'

1,000,000

'

64,194

'

'

'

Exercise price of warrants (in dollars per share)

'

'

'

'

$0.01

'

'

'

'

'

'

'

'

'

$0.01

'

$7.01

'

'

'

Numerator used to determine number of securities called by warrants or rights in qualified financing

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,000

'

'

'

'

'

Fair value of embedded compound derivative

'

'

'

'

'

'

'

'

'

'

'

23,000

23,000

'

'

'

'

'

'

'

Beneficial conversion feature

'

'

'

'

'

'

'

'

2,071,000

'

'

'

'

'

'

'

'

'

'

'

Fair value of warrants

'

5,843,000

'

'

'

'

'

'

'

'

'

'

'

'

1,171,000

'

'

'

'

'

Reduction of additional paid-in capital for extinguishment of convertible debt with beneficial conversion feature

'

'

'

'

'

'

'

'

'

'

1,150,000

'

'

'

'

'

'

'

'

'

Gain on extinguishment

-22,000

'

'

'

'

'

'

'

'

'

22,000

'

'

'

'

'

'

'

'

'

Fair value of Series B Preferred issued upon conversion

'

'

'

'

'

'

'

'

'

'

'

'

'

5,013,000

'

'

'

'

'

'

Number of term loans

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2

'

'

'

'

Aggregate principal amount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

15,000,000

'

7,500,000

7,500,000

Number of monthly repayment installments

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'18 months

'

'

Maximum amount of regularly scheduled installment

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,000,000

'

'

'

Rate of common stock (per share)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$8.06

'

'

'

Number of consecutive trading days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'7 days

'

'

'

'

Maximum percentage of company's trading volume

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

15.00%

'

'

'

'

Number of consecutive trading days for calculating the company's total volume

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

22

'

'

'

'

Percentage of prepayment fees

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2.00%

'

'

'

'

Amount of prepayment fees, in case loan is repaid after 18 months

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0

'

'

'

'

Percentage of fees payable on the aggregate principal amount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3.00%

'

'

'

'

Warrants_Details

Warrants (Details) (USD $)

Dec. 31, 2013

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Apr. 30, 2014

Sep. 30, 2014

Apr. 30, 2014

Sep. 30, 2014

Dec. 31, 2013

Dec. 31, 2013

Apr. 15, 2014

Sep. 30, 2014

Mar. 31, 2014

Mar. 10, 2014

Sep. 30, 2014

In Thousands, except Share data, unless otherwise specified

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Series A Convertible Preferred Stock [Member]

Series A Convertible Preferred Stock [Member]

Series B Convertible Preferred Stock [Member]

Series B Convertible Preferred Stock [Member]

Series A Preferred Stock Warrants Exercise Price Dollars 1.00 [Member]

Series A Preferred Stock Warrants Exercise Price Dollars 0.01 [Member]

Series A Preferred Stock Or Qualified Financing Securities Warrants Exercise Price Dollars 0.01 [Member]

Warrant [Member]

Convertible Debt Issued 2014 [Member]

Convertible Debt Issued 2014 [Member]

Hercules Notes Member

Exercise Price 7.55 [Member]

Exercise Price 0.08 [Member]

Exercise price 7.01 [Member]

Series B Convertible Preferred Stock [Member]

Series A Preferred Stock Warrants Exercise Price Dollars 0.01 [Member]

Series A Preferred Stock Or Qualified Financing Securities Warrants Exercise Price Dollars 0.01 [Member]

Warrants to Purchase Series A Preferred and Common Stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Aggregate principal amount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$15,000

Number of securities that warrants may be converted into

'

20,953

1,043

64,194

'

'

'

'

462,399

4,805,327

787,402

'

1,000,000

1,000,000

64,194

Exercise price of warrants (in dollars per share)

'

$7.55

$0.08

$7.01

'

'

'

'

$1

$0.01

$0.01

'

$0.01

$0.01

$7.01

Fair value of warrants

5,843

'

'

'

'

'

'

'

311

5,532

'

'

1,171

1,171

'

Warrants, term

'

'

'

'

'

'

'

'

'

'

'

'

'7 years

'

'5 years

Number of shares issued upon exercise of warrants

'

'

'

'

5,101,816

5,101,816

787,402

787,402

'

'

'

'

'

'

'

Assumptions to estimate the fair value of warrants

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise price

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$7.01

Fair value of warrants

'

'

'

'

'

'

'

'

'

'

'

$248

'

'

'

Expected volatility

'

'

'

'

'

'

'

'

'

'

'

61.68%

'

'

'

Expected term

'

'

'

'

'

'

'

'

'

'

'

'5 years

'

'

'

Risk-free interest rate

'

'

'

'

'

'

'

'

'

'

'

1.78%

'

'

'

Fair_Value_Measurements_Detail

Fair Value Measurements (Details) (Fair Value, Measurements, Recurring [Member], Estimate of Fair Value Measurement [Member], USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Assets	'	'
Cash and cash equivalents	$23,681	$1,798
Total assets	23,681	1,798
Liabilities	'	'
Warrant liability	'	5,843
Total liabilities	'	5,843
Fair Value, Inputs, Level 1 [Member]	'	'
Assets	'	'
Cash and cash equivalents	23,681	1,798
Total assets	23,681	1,798
Fair Value, Inputs, Level 3 [Member]	'	'
Liabilities	'	'
Warrant liability	'	5,843
Total liabilities	'	$5,843

Fair_Value_Measurements_Detail1

Fair Value Measurements (Details 2) (USD $)

Jul. 15, 2014

Sep. 30, 2014

Jul. 15, 2014

Jul. 15, 2014

Jul. 15, 2014

Jul. 15, 2014

Jun. 30, 2014

Apr. 15, 2014

Mar. 31, 2014

Dec. 31, 2013

Jun. 30, 2014

Apr. 15, 2014

Mar. 31, 2014

Mar. 10, 2014

Jun. 30, 2014

Apr. 15, 2014

Mar. 31, 2014

Mar. 10, 2014

Apr. 15, 2014

Mar. 31, 2014

Dec. 31, 2013

Jun. 30, 2014

Apr. 15, 2014

Mar. 31, 2014

Dec. 31, 2013

Sep. 30, 2014

Mar. 10, 2014

Apr. 15, 2014

Mar. 31, 2014

Mar. 10, 2014

Apr. 15, 2014

Mar. 31, 2014

Mar. 10, 2014

Apr. 15, 2014

Mar. 31, 2014

Mar. 10, 2014

In Thousands, except Per Share data, unless otherwise specified

Warrant [Member]

Warrant [Member]

Warrant [Member]

Warrant [Member]

Warrant [Member]

Warrant [Member]

Warrant [Member]

Warrant [Member]

Warrant [Member]

Warrant [Member]

Warrant [Member]

Warrant [Member]

Warrant [Member]

Warrant [Member]

Warrant [Member]

Warrant [Member]

Warrant [Member]

Warrant [Member]

Warrant [Member]

Warrant [Member]

Warrant [Member]

Warrant [Member]

Warrant [Member]

Warrant [Member]

Warrant [Member]

Embedded Derivative Financial Instruments [Member]

Embedded Derivative Financial Instruments [Member]

Embedded Derivative Financial Instruments [Member]

Embedded Derivative Financial Instruments [Member]

Embedded Derivative Financial Instruments [Member]

Embedded Derivative Financial Instruments [Member]

Embedded Derivative Financial Instruments [Member]

Embedded Derivative Financial Instruments [Member]

Embedded Derivative Financial Instruments [Member]

Embedded Derivative Financial Instruments [Member]

Embedded Derivative Financial Instruments [Member]

Fair Value, Inputs, Level 3 [Member]

Minimum [Member]

Minimum [Member]

Maximum [Member]

Maximum [Member]

Hybrid Method Valuation Technique [Member]

Hybrid Method Valuation Technique [Member]

Hybrid Method Valuation Technique [Member]

Hybrid Method Valuation Technique [Member]

Hybrid Method Valuation Technique [Member]

Hybrid Method Valuation Technique [Member]

Hybrid Method Valuation Technique [Member]

Hybrid Method Valuation Technique [Member]

Hybrid Method Valuation Technique [Member]

Hybrid Method Valuation Technique [Member]

Hybrid Method Valuation Technique [Member]

Hybrid Method Valuation Technique [Member]

Discounted Cash Flow Valuation Technique [Member]

Discounted Cash Flow Valuation Technique [Member]

Discounted Cash Flow Valuation Technique [Member]

Option Pricing Method [Member]

Option Pricing Method [Member]

Option Pricing Method [Member]

Option Pricing Method [Member]

Fair Value, Inputs, Level 3 [Member]

Convertible Debt Issued 2014 [Member]

With And Without Approach Technique [Member]

With And Without Approach Technique [Member]

With And Without Approach Technique [Member]

With And Without Approach Technique [Member]

With And Without Approach Technique [Member]

With And Without Approach Technique [Member]

With And Without Approach Technique [Member]

With And Without Approach Technique [Member]

With And Without Approach Technique [Member]

Fair Value, Inputs, Level 3 [Member]

Fair Value, Inputs, Level 3 [Member]

Fair Value, Inputs, Level 3 [Member]

Fair Value, Inputs, Level 3 [Member]

Minimum [Member]

Minimum [Member]

Minimum [Member]

Minimum [Member]

Maximum [Member]

Maximum [Member]

Maximum [Member]

Maximum [Member]

Fair Value, Inputs, Level 3 [Member]

Fair Value, Inputs, Level 3 [Member]

Fair Value, Inputs, Level 3 [Member]

Fair Value, Inputs, Level 3 [Member]

Fair Value, Inputs, Level 3 [Member]

Fair Value, Inputs, Level 3 [Member]

Fair Value, Inputs, Level 3 [Member]

Fair Value, Inputs, Level 3 [Member]

Fair Value, Inputs, Level 3 [Member]

Fair Value, Inputs, Level 3 [Member]

Minimum [Member]

Minimum [Member]

Minimum [Member]

Maximum [Member]

Maximum [Member]

Maximum [Member]

item

item

item

item

Fair Value, Inputs, Level 3 [Member]

Fair Value, Inputs, Level 3 [Member]

Fair Value, Inputs, Level 3 [Member]

Fair Value, Inputs, Level 3 [Member]

Fair Value, Inputs, Level 3 [Member]

Fair Value, Inputs, Level 3 [Member]

Fair Value, Inputs, Level 3 [Member]

Fair Value, Inputs, Level 3 [Member]

Fair Value, Inputs, Level 3 [Member]

Fair Value, Inputs, Level 3 [Member]

Fair Value, Inputs, Level 3 [Member]

Fair Value, Inputs, Level 3 [Member]

Fair Value, Inputs, Level 3 [Member]

Fair Value, Inputs, Level 3 [Member]

Quantitative information for Level 3 Fair Value Measurements Liabilities

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of possible outcomes considered under valuation model

'

'

'

'

'

'

2

2

2

2

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Discount rate (as a percent)

'

'

'

'

'

'

'

'

'

'

'

21.00%

25.00%

25.00%

'

30.00%

30.00%

30.00%

22.00%

30.00%

35.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Liquidity

'

'

'3 years 6 months 11 days

'

'5 years 1 month 6 days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'2 years 3 months

'2 years 5 months 16 days

'2 years 6 months 11 days

'2 years 9 months

'

'

'

'

'

'

'

'

'

'

'

Annual volatility (as a percent)

'

'

61.58%

'

64.96%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

59.00%

59.00%

58.00%

53.00%

'

'

'

'

'

'

'

'

'

'

'

Fair Value Assumptions using Black-Scholes

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair value of warrants

$167

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise price

'

'

'

$0.08

'

$7.55

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Underlying stock value

$11.80

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Expected volatility

'

'

61.58%

'

64.96%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

59.00%

59.00%

58.00%

53.00%

'

'

'

'

'

'

'

'

'

'

'

Risk-free interest rate

'

'

1.34%

'

1.70%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Expected term

'

'

'3 years 6 months 11 days

'

'5 years 1 month 6 days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'2 years 3 months

'2 years 5 months 16 days

'2 years 6 months 11 days

'2 years 9 months

'

'

'

'

'

'

'

'

'

'

'

Changes in fair value of liabilities in level 3 inputs

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Beginning balance

'

5,843

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

Warrant issuance

'

1,171

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

23

'

'

'

'

'

'

'

'

'

'

Change in fair value

'

222

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrant exercises

'

-7,069

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Reclassification to equity

'

-167

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Derecognition of embedded compound derivative

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-23

'

'

'

'

'

'

'

'

'

'

Ending balance

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

Notes issued

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$5,000

'

'

'

'

'

'

'

'

'

Probability weighted value for common stock (as a percent)

'

'

'

'

'

'

'

'

'

'

20.00%

30.00%

45.00%

45.00%

80.00%

70.00%

55.00%

55.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Discount for lack of marketability (as a percent)

'

'

'

'

'

'

'

'

'

'

5.00%

11.00%

10.00%

10.00%

30.00%

34.00%

28.00%

28.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Probability of occurrence (as a percent)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0.00%

5.00%

5.00%

100.00%

50.00%

50.00%

Market yield (as a percent)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

25.00%

25.00%

25.00%

'

'

'

'

'

'

Recovery rate (as a percent)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

31.00%

31.00%

31.00%

47.00%

47.00%

47.00%

Convertible_Preferred_Stock_De

Convertible Preferred Stock (Details) (USD $)	0 Months Ended	1 Months Ended	9 Months Ended
In Thousands, except Share data, unless otherwise specified	Apr. 15, 2014	Apr. 30, 2014	Sep. 30, 2014
			director
			item
Convertible Debt Issued 2014 [Member]	'	'	'
Convertible Preferred Stock	'	'	'
Outstanding principal amount converted	5,000	$5,000	'
Outstanding interest amount converted	13	13	'
Series A Convertible Preferred Stock [Member]	'	'	'
Convertible Preferred Stock	'	'	'
Issuance of shares	'	'	13,184,383
Number of classes holders entitled to vote as for all matters except approval of certain major actions and election of directors	'	'	1
Number of directors that holders are entitled to vote for as a separate class	'	'	3
Dividend rate (as a percent)	'	'	8.00%
Dividends declared	'	'	0
Multiple of original issuance price used for determination of liquidation rights	'	'	3
Adjustment to carrying amount of temporary equity for liquidation event	'	'	0
Series B Convertible Preferred Stock [Member]	'	'	'
Convertible Preferred Stock	'	'	'
Issuance of shares	'	24,409,444	24,409,444
Proceeds from issuance of shares	'	31,000	'
Number of shares issued upon conversion of debt	3,947,363	3,947,363	'
Number of classes holders entitled to vote as for all matters except approval of certain major actions and election of directors	'	'	1
Number of directors that holders are entitled to vote for as a separate class	'	'	1
Number of directors that holders are entitled to vote for as a separate class if common stock of company or affiliate not listed on public trading platform by October 15, 2014	'	'	2
Dividend rate (as a percent)	'	'	8.00%
Dividends declared	'	'	0
Multiple of original issuance price used for determination of liquidation rights	'	'	3
Adjustment to carrying amount of temporary equity for liquidation event	'	'	$0
Common Class A [Member]	'	'	'
Convertible Preferred Stock	'	'	'
Number of directors that holders are entitled to vote for as a separate class	'	'	1

StockBased_Compensation_Detail

Stock-Based Compensation (Details) (USD $)

3 Months Ended

9 Months Ended

0 Months Ended

3 Months Ended

0 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

1 Months Ended

In Thousands, except Share data, unless otherwise specified

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Jul. 15, 2014

Sep. 30, 2014

Jul. 15, 2014

Jul. 15, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2013

Aug. 31, 2014

Sep. 30, 2014

Apr. 01, 2014

Mar. 31, 2014

Zalicus [Member]

Zalicus [Member]

Minimum [Member]

Maximum [Member]

Employees Of Acquirees [Member]

Non Employees Of Acquirees [Member]

Non Employees Of Acquirees [Member]

Employee And Directors Stock Options [Member]

Employee And Directors Stock Options [Member]

Employee And Directors Stock Options [Member]

Employee And Directors Stock Options [Member]

Employee And Directors Stock Options [Member]

Employee And Directors Stock Options [Member]

Employee And Directors Stock Options [Member]

Employee And Directors Stock Options [Member]

Employee And Directors Stock Options [Member]

Employee And Directors Stock Options [Member]

Employee And Directors Stock Options [Member]

2014 Plan

2014 Plan

2011 Plan

2011 Plan

Zalicus [Member]

Zalicus [Member]

Zalicus [Member]

Zalicus [Member]

Zalicus [Member]

Zalicus [Member]

Minimum [Member]

Minimum [Member]

Minimum [Member]

Maximum [Member]

Maximum [Member]

Maximum [Member]

Stock-Based Compensation

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Authorized number of shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,504,752

740,470

Increase in number of shares available for issuance

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,000,000

'

'

'

Shares available for issuance

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,818,071

'

'

Stock-based compensation expense

$943

$35

$1,314

$93

'

$355

'

'

$355

$185

$283

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Acquisition-date fair value of assumed Zalicus equity awards attributable to precombination services

'

'

'

'

220

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of Options

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Outstanding at the beginning of the period

'

'

'

'

'

'

'

'

'

'

'

'

'

458,871

'

'

'

'

'

'

'

'

'

'

'

'

Granted

'

'

'

'

'

'

'

'

'

'

'

'

'

1,143,076

'

'

'

'

'

'

'

'

'

'

'

'

Options assumed through Zalicus merger

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

134,454

'

'

'

'

'

'

'

'

'

'

Exercised

'

'

'

'

'

'

'

'

'

'

'

'

'

-98,405

'

'

'

'

'

'

'

'

'

'

'

'

Cancelled

'

'

'

'

'

'

'

'

'

'

'

'

'

-52,098

'

'

'

'

'

'

'

'

'

'

'

'

Outstanding at the end of the period

'

'

'

'

'

'

'

'

'

'

'

1,585,898

'

1,585,898

'

'

'

'

'

'

'

'

'

'

'

'

Vested and expected to vest at end of period

'

'

'

'

'

'

'

'

'

'

'

1,534,073

'

1,534,073

'

'

'

'

'

'

'

'

'

'

'

'

Exercisable at end of period

'

'

'

'

'

'

'

'

'

'

'

289,667

'

289,667

'

'

'

'

'

'

'

'

'

'

'

'

Weighted-Average Exercise Price

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Outstanding at the beginning of the period

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.96

'

'

'

'

'

'

'

'

'

'

'

'

Granted

'

'

'

'

'

'

'

'

'

'

'

'

'

$7.95

'

'

'

'

'

'

'

'

'

'

'

'

Options assumed through Zalicus merger

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$72.02

'

'

'

'

'

'

'

'

'

'

Exercised

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.91

'

'

'

'

'

'

'

'

'

'

'

'

Cancelled

'

'

'

'

'

'

'

'

'

'

'

'

'

$16.85

'

'

'

'

'

'

'

'

'

'

'

'

Outstanding at the end of the period

'

'

'

'

'

'

'

'

'

'

'

$11.50

'

$11.50

'

'

'

'

'

'

'

'

'

'

'

'

Vested and expected to vest at end of period

'

'

'

'

'

'

'

'

'

'

'

$11.65

'

$11.65

'

'

'

'

'

'

'

'

'

'

'

'

Exercisable at end of period

'

'

'

'

'

'

'

'

'

'

'

$5.97

'

$5.97

'

'

'

'

'

'

'

'

'

'

'

'

Weighted-Average Remaining Contractual Term

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Outstanding at end of period

'

'

'

'

'

'

'

'

'

'

'

'

'

'9 years 1 month 6 days

'

'

'

'

'

'

'

'

'

'

'

'

Vested and expected to vest at end of period

'

'

'

'

'

'

'

'

'

'

'

'

'

'9 years

'

'

'

'

'

'

'

'

'

'

'

'

Exercisable at end of period

'

'

'

'

'

'

'

'

'

'

'

'

'

'7 years 6 months

'

'

'

'

'

'

'

'

'

'

'

'

Aggregate Instrinsic Value

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Outstanding at end of period

'

'

'

'

'

'

'

'

'

'

'

7,810

'

7,810

'

'

'

'

'

'

'

'

'

'

'

'

Vested and expected to vest at end of period

'

'

'

'

'

'

'

'

'

'

'

7,556

'

7,556

'

'

'

'

'

'

'

'

'

'

'

'

Exercisable at end of period

'

'

'

'

'

'

'

'

'

'

'

1,440

'

1,440

'

'

'

'

'

'

'

'

'

'

'

'

Weighted average fair value

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Weighted average grant-date fair value of options granted during the period

'

'

'

'

'

'

'

'

'

'

'

'

'

$6.01

'

'

'

'

'

'

'

'

'

'

'

'

Unrecognized stock-based compensation expense

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Unrecognized stock-based compensation expense

'

'

'

'

'

'

'

'

'

'

'

$4,992

'

$4,992

'

'

'

'

'

'

'

'

'

'

'

'

Unrecognized stock-based compensation expense, Recognition period

'

'

'

'

'

'

'

'

'

'

'

'

'

'3 years 5 months 23 days

'

'

'

'

'

'

'

'

'

'

'

'

Weighted-average assumptions

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Risk-free interest rate

'

'

'

'

1.91%

'

'

'

'

'

'

'

1.81%

'

'

'

1.95%

1.91%

1.09%

2.01%

2.09%

1.81%

'

'

'

'

Expected volatility

'

'

'

'

66.02%

'

'

'

'

'

'

'

66.99%

'

66.99%

'

65.84%

64.07%

'

65.94%

66.07%

'

'

'

'

'

Expected term

'

'

'

'

'

'

'1 month 6 days

'6 years

'

'

'

'6 years

'6 years

'6 years

'6 years

'

'

'

'

'

'

'

'

'

'

'

Expected dividend yield

'

'

'

'

'

'

'

'

'

'

'

0.00%

0.00%

0.00%

0.00%

'

'

'

'

'

'

'

'

'

'

'

StockBased_Compensation_Detail1

Stock-Based Compensation (Details 2) (USD $)

3 Months Ended

9 Months Ended

1 Months Ended

3 Months Ended

9 Months Ended

0 Months Ended

9 Months Ended

1 Months Ended

In Thousands, except Share data, unless otherwise specified

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2014

Apr. 30, 2014

Sep. 30, 2014

Jun. 30, 2014

Sep. 30, 2014

Apr. 15, 2014

Sep. 30, 2014

Sep. 30, 2014

Vendor For Consulting Services [Member]

Restricted Stock [Member]

Restricted Stock [Member]

Restricted Stock [Member]

Restricted Stock [Member]

Restricted Stock [Member]

Restricted Stock [Member]

Restricted Stock [Member]

Restricted Stock [Member]

Vendor For Consulting Services [Member]

Vendor For Consulting Services [Member]

Vendor For Consulting Services [Member]

Vendor For Consulting Services [Member]

Vendor For Consulting Services [Member]

Vendor For Consulting Services [Member]

Vendor For Consulting Services [Member]

Share-based Compensation Award, Tranche One [Member]

Share-based Compensation Award, Tranche One [Member]

Share-based Compensation Award, Tranche Two [Member]

Stock-Based Compensation

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock-based compensation expense

$943

$35

$1,314

$93

'

'

'

'

'

'

'

'

'

Shares granted

'

'

'

'

'

58,560

53,036

'

'

'

'

'

'

Vesting percentage

'

'

'

'

'

'

'

50.00%

25.00%

75.00%

'

'

'

Shares vested during the period

'

'

'

'

'

-45,301

'

'

'

'

13,259

'

'

Expense recorded

'

'

'

'

'

'

'

'

'

'

'

98

185

Upfront fee

'

'

'

'

200

'

'

'

'

'

'

'

'

Monthly consulting fee

'

'

'

'

$25

'

'

'

'

'

'

'

'

Period of consulting

'

'

'

'

'18 months

'

'

'

'

'

'

'

'

StockBased_Compensation_Detail2

Stock-Based Compensation (Details 3) (USD $)	3 Months Ended		9 Months Ended			3 Months Ended	9 Months Ended	0 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014	Jul. 15, 2014	Jul. 14, 2014
					Restricted Stock [Member]	Restricted Stock Units (RSUs) [Member]	Restricted Stock Units (RSUs) [Member]	Restricted Stock Units (RSUs) [Member]	Restricted Stock Units (RSUs) [Member]
								Zalicus [Member]	Zalicus [Member]
Stock-Based Compensation	'	'	'	'	'	'	'	'	'
Stock-based compensation expense	$943	$35	$1,314	$93	'	$277	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares	'	'	'	'	'	'	'	'	'
Granted	'	'	'	'	58,560	'	27,777	25,000	'
Vested	'	'	'	'	-45,301	'	-27,777	'	'
Cancelled	'	'	'	'	'	'	'	'	52,777
Non-vested at ending period	'	'	'	'	13,259	'	'	'	'
Weighted Average Grant Date Fair Value	'	'	'	'	'	'	'	'	'
Granted	'	'	'	'	$5.08	'	$11.80	'	'
Vested	'	'	'	'	$5.08	'	$11.80	'	'
Non-vested at ending period	'	'	'	'	$5.08	'	'	'	'

Income_Taxes_Details

Income Taxes (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Income tax benefit (expense)	$21	$16	($18)	$16
Deferred Tax Liabilities, Net	2,166	'	2,166	'
Alternative minimum tax	'	'	20	'
Deferred Income Tax Expense (Benefit)	'	'	138	'
BRAZIL	'	'	'	'
Income tax benefit (expense)	'	'	-76	'
SWITZERLAND	'	'	'	'
Offset by withholding income tax	25	'	100	'
In Process Research and Development [Member]	'	'	'	'
Income tax benefit (expense)	$46	'	'	'

Committments_Details

Committments (Details) (USD $)	5 Months Ended	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2014
Commitments	'	'
Term of lease	'	'7 years
Rent expense per month	'	$38
Incentive received from leasehold improvement	477	'
Capital Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]	'	'
Remainder of 2014	111	111
2015	448	448
2016	456	456
2017	464	464
2018	472	472
2019 and thereafter	1,297	1,297
Total	$3,248	$3,248

Net_loss_per_share_Details

Net loss per share (Details)	3 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Convertible Preferred Stock [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share	'	'
Securities excluded from the computation of diluted weighted-average shares outstanding	'	27,248,746
Convertible Notes Payable [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share	'	'
Securities excluded from the computation of diluted weighted-average shares outstanding	'	7,770,905
Employee Stock Option [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share	'	'
Securities excluded from the computation of diluted weighted-average shares outstanding	1,585,898	458,871
Warrant [Member] | Preferred Stock [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share	'	'
Securities excluded from the computation of diluted weighted-average shares outstanding	'	4,267,727
Warrant [Member] | Common Stock [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share	'	'
Securities excluded from the computation of diluted weighted-average shares outstanding	86,190	'
Restricted Stock [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share	'	'
Securities excluded from the computation of diluted weighted-average shares outstanding	13,259	'

Legal_Proceedings_Details

Legal Proceedings (Details) (USD $)	0 Months Ended		3 Months Ended	0 Months Ended
In Thousands, unless otherwise specified	Oct. 27, 2014	2-May-14	Sep. 30, 2014	16-May-14
	Zalicus Shareholder Litigation Filed In Massachusetts [Member]	Zalicus Shareholder Litigation Filed In Massachusetts [Member]	Zalicus Shareholder Litigation Filed In Massachusetts [Member]	Zalicus Shareholder Litigation Filed In Delaware [Member]
		lawsuit	lawsuit	lawsuit
Legal Proceedings	'	'	'	'
Number of putative class action lawsuits filed	'	3	'	3
Number of putative class action lawsuits voluntarily dismissed by plaintiffs	'	'	1	'
Number of putative class action lawsuits consolidated into single action by plaintiffs	'	'	2	'
Loss contingency fees and expenses	$350	'	'	'